WO2020144615A1 - Prostate neoantigens and their uses - Google Patents

Prostate neoantigens and their uses Download PDF

Info

Publication number
WO2020144615A1
WO2020144615A1 PCT/IB2020/050145 IB2020050145W WO2020144615A1 WO 2020144615 A1 WO2020144615 A1 WO 2020144615A1 IB 2020050145 W IB2020050145 W IB 2020050145W WO 2020144615 A1 WO2020144615 A1 WO 2020144615A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
polypeptide
fragment
disclosure
fragments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2020/050145
Other languages
English (en)
French (fr)
Inventor
Kurtis E. Bachman
Vipul BHARGAVA
Darryl L. DAVIS
Vinod KRISHNA
Guido LEONI
David POCALYKO
Pegah SAFABAKHSH
Manuel Sepulveda
Derick Siegel
Marco Gottardis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69191089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2020144615(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to EA202191919A priority Critical patent/EA202191919A1/ru
Priority to PH1/2021/551633A priority patent/PH12021551633A1/en
Priority to PE2021001152A priority patent/PE20211660A1/es
Priority to CA3126462A priority patent/CA3126462A1/en
Priority to SG11202107274VA priority patent/SG11202107274VA/en
Priority to AU2020207641A priority patent/AU2020207641B2/en
Priority to CR20210370A priority patent/CR20210370A/es
Priority to MX2021008392A priority patent/MX2021008392A/es
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Priority to JP2021539906A priority patent/JP7524197B2/ja
Priority to KR1020217025212A priority patent/KR20210113655A/ko
Priority to CN202080020511.3A priority patent/CN113573729A/zh
Priority to BR112021013507A priority patent/BR112021013507A2/pt
Priority to EP20701888.8A priority patent/EP3908311A1/en
Publication of WO2020144615A1 publication Critical patent/WO2020144615A1/en
Priority to IL284561A priority patent/IL284561A/en
Priority to JOP/2021/0186A priority patent/JOP20210186A1/ar
Anticipated expiration legal-status Critical
Priority to CONC2021/0010006A priority patent/CO2021010006A2/es
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001195—Prostate specific membrane antigen [PSMA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Definitions

  • Prostate cancer is the most common non-cutaneous malignancy in men and the second leading cause of death in men from cancer in the western world. Prostate cancer results from the uncontrolled growth of abnormal cells in the prostate gland. Once a prostate cancer tumor develops, androgens such as testosterone promote prostate cancer growth. At its early stages, localized prostate cancer is often curable with local therapy including, for example, surgical removal of the prostate gland and radiotherapy. However, when local therapy fails to cure prostate cancer, as it does in up to a third of men, the disease progresses into incurable metastatic disease.
  • the disclosure provides an isolated polynucleotide encoding a polypeptide of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139,
  • the disclosure also provides an isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170,
  • the disclosure also provides an isolated heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112,
  • the disclosure also provides an isolated heterologous polynucleotide encoding a heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169,
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173,
  • the disclosure also provides an isolated heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15,
  • the disclosure also provides a vector comprising
  • polynucleotide encoding one or more polypeptides of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67,
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155,
  • a heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166,
  • the disclosure also provides a recombinant human adenovirus (rAd) comprising the vector of the disclosure.
  • the disclosure also provides a recombinant modified vaccinia Ankara (rMVA) comprising the vector of the disclosure.
  • rMVA modified vaccinia Ankara
  • the disclosure also provides a recombinant great ape adenovirus (rGAd) comprising the vector of the disclosure.
  • rGAd great ape adenovirus
  • the disclosure also provides a cell comprising or transduced with the vector of the disclosure or the recombinant virus of the disclosure.
  • the disclosure also provides a vaccine comprising the polynucleotide of the disclosure.
  • the disclosure also provides a vaccine comprising the heterologous polynucleotide of the disclosure.
  • the disclosure also provides a vaccine comprising the polypeptide of the disclosure.
  • the disclosure also provides a vaccine comprising the heterologous polypeptide of the disclosure.
  • the disclosure also provides a vaccine comprising the vector of the disclosure.
  • the disclosure also provides a vaccine comprising the rAd of the disclosure.
  • the disclosure also provides a vaccine comprising the rMVA of the disclosure.
  • the disclosure also provides a vaccine comprising the rGAd of the disclosure.
  • the disclosure also provides a vaccine comprising the cell of the disclosure.
  • the disclosure also provides a pharmaceutical composition
  • a pharmaceutical composition comprising the vaccine of the disclosure and a pharmaceutically acceptable carrier or adjuvant.
  • the disclosure also provides a kit comprising one or more vaccines of the disclosure or the pharmaceutical composition of the disclosure.
  • the disclosure also provides a method of preventing or treating a prostate cancer in a subject, comprising administering to the subject a therapeutically effective amount of one or more vaccines of the disclosure or one or more pharmaceutical composition of the disclosure.
  • the disclosure also provides a method of inducing an immune response against one or more polypeptides of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167,
  • the disclosure also provides an isolated heterologous polynucleotide encoding two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof.
  • the disclosure also provides an isolated heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26,
  • polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof.
  • the disclosure also provides a vector comprising:
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27,
  • polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265,
  • heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • heterologous polynucleotide encoding the heterologous polypeptide of SEQ ID NOs: 541, 550, 554, 555, 556, 623 or 624;
  • heterologous polynucleotide encoding the heterologous polypeptide of SEQ ID NOs: 543, 552, 557, 558, 559, 625 or 626;
  • heterologous polynucleotide comprising a polynucleotide sequence of SEQ ID NO: 542 or SEQ ID NO: 551; or
  • heterologous polynucleotide comprising the polynucleotide sequence of SEQ ID NO: 544 or SEQ ID NO: 553.
  • the disclosure also provides a recombinant human adenovirus (rAd), comprising:
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,
  • polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11,
  • polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11,
  • polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522, 523, 524, 525, 485, 486, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539 and 540, and fragments thereof.
  • the disclosure also provides a recombinant great ape adenovirus (rGAd), comprising: a heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof;
  • a heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450, 453, 455, 380, 344, 212, 350, 214, 216, 222, 220, 226, 346, 354, 236, 224, 168, 172, 20, 24 and 178, and fragments thereof;
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • the disclosure also provides a recombinant modified vaccinia Ankara (rMVA), comprising:
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof;
  • a heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450, 453, 455, 380, 344, 212, 350, 214, 216, 222, 220, 226, 346, 354, 236, 224, 168, 172, 20, 24 and 178, and fragments thereof;
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • the disclosure also provides a vaccine comprising a rAd, comprising
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof;
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • the disclosure also provides a vaccine comprising rGAd20, comprising
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof;
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • the disclosure also provides a vaccine comprising rMVA comprising
  • heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof; a heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479,
  • heterologous polynucleotide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520,
  • the disclosure also provides a vaccine comprising a heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437,
  • the disclosure also provides a method of treating or preventing a prostate cancer in a subject, comprising:
  • a vaccine comprising a heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof as a prime; and
  • a vaccine comprising a heterologous polynucleotide encoding a heterologous polypeptide comprising two, three, four, five, six, seven, eight, nine, ten, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, or 41 polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof as a boost; thereby treating or preventing the prostate cancer in the subject.
  • the disclosure also provides a vaccine comprising a heterologous polynucleotide encoding a heterologous polypeptide of SEQ ID NOs: 541, 550, 554, 555, 556, 623 or 624.
  • the disclosure also provides a vaccine comprising a heterologous polynucleotide encoding a heterologous polypeptide of SEQ ID NOs: 543, 552, 557, 558, 559, 625 or 626.
  • the disclosure also provides a method of treating or preventing a prostate cancer in a subject, comprising administering to the subject
  • a first vaccine comprising a first heterologous polynucleotide encoding a first heterologous polypeptide, wherein the first heterologous polypeptide comprises two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177; and
  • a second vaccine comprising a second heterologous polynucleotide encoding a second heterologous polypeptide, wherein the second heterologous polypeptide comprises two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439,
  • first heterologous polypeptide and the second heterologous polypeptide have distinct amino acid sequences.
  • the disclosure also provides a method of inducing an immune response in a subject, comprising administering to the subject
  • a first vaccine comprising a first heterologous polynucleotide encoding a first heterologous polypeptide, wherein the first heterologous polypeptide comprises two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439,
  • a second vaccine comprising a second heterologous polynucleotide encoding a second heterologous polypeptide
  • the second heterologous polypeptide comprises two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177; wherein the first heterologous polypeptide and the second heterologous polypeptide have distinct amino acid sequences.
  • the disclosure also provides an isolated proteinaceous molecule that specifically binds the polypeptide of the disclosure.
  • the disclosure also provides a method of preventing or treating a prostate cancer in a subject, comprising administering to the subject the proteinaceous molecule of the disclosure.
  • the above embodiments of the invention encompass polypeptides comprising, in addition to the specifically recited polypeptides and fragments thereof, also additional polypeptide sequences, including one or more polypeptides different from those specifically recited.
  • the above embodiments of the invention also encompass polynucleotides comprising, in addition to the specifically recited polynucleotides and fragments thereof, also additional polynucleotide sequences, including one or more polynucleotides different from those specifically recited.
  • FIG. 1 shows a cartoon of chimeric read-through fusions between Gene A and Gene B.
  • Neoantigenic peptide sequences arise at the breakpoint junction.
  • FIG. 2 shows a cartoon of gene fusions resulting from chromosomal alteration, such as DNA translocations.
  • FIG. 3 shows a cartoon of splice variants with alternative 5’ or 3’ splice sites, retained introns, excluded exons or alternative terminations or insertions.
  • FIG. 4 shows the cartoon for approach of identification of splice variants.
  • FIG. 5A shows a flow cytometry dot plot depicting TNFa + IFNy + CD8 + T cell frequencies in PBMC samples after no stimulation (DMSO).
  • FIG. 5B shows a flow cytometry dot plot depicting TNFa + IFNy + CD8 + T cell frequencies in PBMC samples after stimulating with CEF peptide.
  • FIG. 5C shows a flow cytometry dot plot depicting TNFa + IFNy + CD8 + T cell frequencies in PBMC samples after stimulation with P 16.
  • FIG. 5D shows a flow cytometry dot plot depicting TNFa + IFNy + CD8 + T cell frequencies in PBMC samples after stimulation with P98.
  • FIG. 5E shows a flow cytometry dot plot depicting TNFa + IFNy + CD8 + T cell frequencies in PBMC samples after stimulation with P3 self-antigen.
  • FIG. 6 shows the number of prostate cancer patients whose PBMC samples demonstrated a positive immune response to the specified neoantigens. P3, P6, P7, P9 and P92 represent selfantigens.
  • FIG. 7 shows the number of prostate cancer patients whose PBMC samples demonstrated a positive CD4 + immune response to the specified neoantigens.
  • FIG. 8 shows the number of prostate cancer patients whose PBMC samples demonstrated a positive CD8 + immune response to the specified neoantigens.
  • transitional terms“comprising,”“consisting essentially of,” and“consisting of’ are intended to connote their generally accepted meanings in the patent vernacular; that is, (i) “comprising,” which is synonymous with“including,”“containing,” or“characterized by,” is inclusive or open-ended and does not exclude additional, unrecited elements or method steps; (ii) “consisting of’ excludes any element, step, or ingredient not specified in the claim; and (iii) “consisting essentially of’ limits the scope of a claim to the specified materials or steps“and those that do not materially affect the basic and novel characteristic(s)” of the claimed disclosure.
  • Embodiments described in terms of the phrase“comprising” (or its equivalents) also provide as embodiments those independently described in terms of“consisting of’ and“consisting essentially of.”
  • the phrase“and fragments thereof’ when appended to a list includes fragments of one or more members of the associated list.
  • the list may comprise a Markush group so that, as an example, the phrase“the group consisting of peptides A, B, and C, and fragments thereof’ specifies or recites a Markush group including A, B, C, fragments of A, fragments of B, and/or fragments of C.
  • Isolated refers to a homogenous population of molecules (such as synthetic polynucleotides or polypeptides) which have been substantially separated and/or purified away from other components of the system the molecules are produced in, such as a recombinant cell, as well as a protein that has been subjected to at least one purification or isolation step.
  • molecules such as synthetic polynucleotides or polypeptides
  • isolated refers to a molecule that is substantially free of other cellular material and/or chemicals and encompasses molecules that are isolated to a higher purity, such as to 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% purity.
  • Polynucleotide refers to a synthetic molecule comprising a chain of nucleotides covalently linked by a sugar-phosphate backbone or other equivalent covalent chemistry.
  • cDNA is a typical example of a polynucleotide.
  • Polypeptide or“protein” refers to a molecule that comprises at least two amino acid residues linked by a peptide bond to form a polypeptide. Small polypeptides of less than 50 amino acids may be referred to as“peptides”.
  • Immunogenic fragment refers to a polypeptide that is recognized by cytotoxic T lymphocytes, helper T lymphocytes or B cells when the fragment is in complex with MHC class I or MHC class II molecules.
  • In-frame refers to the reading frame of codons in a first polynucleotide being the same as the reading frame of codons in a second polynucleotide which are joined together to form a heterologous polynucleotide.
  • In-frame heterologous polynucleotide encodes a heterologous polypeptide encoded by both the first polynucleotide and the second
  • Immunogenic refers to a polypeptide that comprises one or more immunogenic fragments.
  • Heterologous refers to two or more polynucleotides or two or more polypeptides that are not found in the same relationship to each other in nature.
  • Heterologous polynucleotide refers to a non-naturally occurring polynucleotide that encodes two or more neoantigens as described herein.
  • Heterologous polypeptide refers to a non-naturally occurring polypeptide comprising two or more neoantigen polypeptides as described herein.
  • Non-naturally occurring refers to a molecule that does not exist in nature.
  • Vector refers to a polynucleotide capable of being duplicated within a biological system or that can be moved between such systems.
  • Vector polynucleotides typically contain elements, such as origins of replication, polyadenylation signal or selection markers, that function to facilitate the duplication or maintenance of these polynucleotides in a biological system.
  • Examples of such biological systems may include a cell, vims, animal, plant, and reconstituted biological systems utilizing biological components capable of duplicating a vector.
  • the polynucleotide comprising a vector may be DNA or RNA molecules or a hybrid of these.
  • “Expression vector” refers to a vector that can be utilized in a biological system or in a reconstituted biological system to direct the translation of a polypeptide encoded by a polynucleotide sequence present in the expression vector.
  • “Viral vector” refers to a vector construct that includes at least one polynucleotide element of viral origin and has the capacity to be packaged into a viral vector particle.
  • Neoantigen refers to a polypeptide that is present in prostate tumor tissue that has at least one alteration that makes it distinct from the corresponding wild-type polypeptide present in non-malignant tissue, e.g., via mutation in a tumor cell or post-translational modification specific to a tumor cell.
  • a mutation can include a frameshift or nonframeshift insertion or deletion, missense or nonsense substitution, splice site alteration, aberrant splice variants, genomic rearrangement or gene fusion, or any genomic or expression alteration giving rise to the neoantigen.
  • Prevalence refers to a percentage of a population studied harboring a prostate neoantigen.
  • Recombinant refers to polynucleotides, polypeptides, vectors, vimses and other macromolecules that are prepared, expressed, created or isolated by recombinant means.
  • Vaccine refers to a composition that comprises one or more immunogenic polypeptides, immunogenic polynucleotides or fragments, or any combination thereof intentionally administered to induce acquired immunity in the recipient (e.g. subject).
  • Treat”,“treating” or“treatment” of a disease or disorder such as cancer refers to accomplishing one or more of the following: reducing the severity and/or duration of the disorder, inhibiting worsening of symptoms characteristic of the disorder being treated, limiting or preventing recurrence of the disorder in subjects that have previously had the disorder, or limiting or preventing recurrence of symptoms in subjects that were previously symptomatic for the disorder.
  • Prevent”,“preventing”,“prevention”, or“prophylaxis” of a disease or disorder means preventing that a disorder occurs in subject.
  • “Therapeutically effective amount” refers to an amount effective, at doses and for periods of time necessary, to achieve a desired therapeutic result.
  • a therapeutically effective amount may vary depending on factors such as the disease state, age, sex, and weight of the individual, and the ability of a therapeutic or a combination of therapeutics to elicit a desired response in the individual. Exemplary indicators of an effective therapeutic or combination of therapeutics that include, for example, improved well-being of the patient.
  • Relapsed refers to the return of a disease or the signs and symptoms of a disease after a period of improvement after prior treatment with a therapeutic.
  • Refractory refers to a disease that does not respond to a treatment.
  • a refractory disease can be resistant to a treatment before or at the beginning of the treatment, or a refractory disease can become resistant during a treatment.
  • Subject includes any human or nonhuman animal.
  • Nonhuman animal includes all vertebrates, e.g., mammals and non-mammals, such as nonhuman primates, sheep, dogs, cats, horses, cows, chickens, amphibians, reptiles, etc.
  • the terms“subject” and“patient” can be used interchangeably herein.
  • “In combination with” means that two or more therapeutic agents are be administered to a subject together in a mixture, concurrently as single agents or sequentially as single agents in any order.
  • Enhance or“induce” when in reference to an immune response refers to increasing the scale and/or efficiency of an immune response or extending the duration of the immune response.
  • the terms are used interchangeably with“augment”.
  • Immuno response refers to any response to an immunogenic polypeptide or polynucleotide or fragment by the immune system of a vertebrate subject.
  • exemplary immune responses include local and systemic cellular as well as humoral immunity, such as cytotoxic T lymphocyte (CTL) responses, including antigen-specific induction of CD8 + CTLs, helper T-cell responses including T-cell proliferative responses and cytokine release, and B-cell responses including antibody response.
  • CTL cytotoxic T lymphocyte
  • binds refer to a proteinaceous molecule binding to an antigen or an epitope within the antigen (e.g. to prostate neoantigen) with greater affinity than for other antigens.
  • the proteinaceous molecule binds to the antigen or the epitope within the antigen with an equilibrium dissociation constant (K D ) of about lxlO 7 M or less, for example about 5xl0 8 M or less, about lxlO 8 M or less, about lxlO 9 M or less, about lxlO 10 M or less, about lxlO 11 M or less, or about lxlO 12 M or less, typically with the K D that is at least one hundred fold less than its K D for binding to a nonspecific antigen (e.g., BSA, casein).
  • K D equilibrium dissociation constant
  • specific binding refers to binding of the proteinaceous molecule to the prostate neoantigen without detectable binding to a wild-type protein the neoantigen is a variant of.
  • “Variant”,“mutant” or“altered” refers to a polypeptide or a polynucleotide that differs from a reference polypeptide or a reference polynucleotide by one or more modifications, for example one or more substitutions, insertions or deletions.
  • “Antibody” refers to an immunoglobulin molecule including monoclonal antibodies including murine, human, humanized and chimeric monoclonal antibodies, antigen-binding fragments, bispecific or multispecific antibodies, dimeric, tetrameric or multimeric antibodies, single chain antibodies, domain antibodies and any other modified configuration of the immunoglobulin molecule that comprises an antigen binding site of the required specificity.
  • “Full length antibody” is comprised of two heavy chains (HC) and two light chains (LC) inter-connected by disulfide bonds as well as multimers thereof (e.g. IgM).
  • Each heavy chain is comprised of a heavy chain variable domain (VH) and a heavy chain constant domain, the heavy chain constant domain comprised of subdomains CHI, hinge, CH2 and CH3.
  • Each light chain is comprised of a light chain variable domain (VL) and a light chain constant domain (CL).
  • the VH and the VL may be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with framework regions (FR).
  • CDR complementarity determining regions
  • FR framework regions
  • Each VH and VL is composed of three CDRs and four FR segments, arranged from amino-to-carboxy- terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • CDR complementarity determining regions
  • CDR “CDR”,“HCDR1”,“HCDR2”,“HCDR3”,“LCDR1”,“LCDR2” and“LCDR3” as used herein includes CDRs defined by any of the methods described supra, Rabat, Chothia, IMGT or AbM, unless otherwise explicitly stated in the specification.
  • Immunoglobulins may be assigned to five major classes, IgA, IgD, IgE, IgG and IgM, depending on the heavy chain constant region amino acid sequence.
  • IgA and IgG are further sub-classified as isotypes IgAl, IgA2, IgGl, IgG2, IgG3 and IgG4.
  • Antibody light chains of any vertebrate species may be assigned to one of two clearly distinct types, namely kappa (K) and lambda (l), based on the amino acid sequences of their constant domains.
  • Antigen-binding fragment refers to a portion of an immunoglobulin molecule that retains the antigen binding properties of the parental full length antibody.
  • Exemplary antigenbinding fragments are heavy chain complementarity determining regions (HCDR) 1, 2 and/or 3, light chain complementarity determining regions (LCDR) 1, 2 and/or 3, the VH, the VL, the VH and the VL, Fab, F(ab')2, Fd and Fv fragments as well as domain antibodies (dAb) consisting of either one VH domain or one VL domain.
  • the VH and the VL domains may be linked together via a synthetic linker to form various types of single chain antibody designs in which the VH/VL domains pair intramolecularly, or intermolecularly in those cases when the VH and VL domains are expressed by separate chains, to form a monovalent antigen binding site, such as single chain Fv (scFv) or diabody; described for example in lnt. Pat. Publ. No. W01998/44001, Int. Pat. Publ. No. WO1988/01649, Int. Pat. Publ. No. WO1994/13804 or Int. Pat. Publ. No. W01992/01047.
  • scFv single chain Fv
  • “Monoclonal antibody” refers to an antibody obtained from a substantially homogenous population of antibody molecules, i.e., the individual antibodies comprising the population are identical except for possible well-known alterations such as removal of C-terminal lysine from the antibody heavy chain or post-translational modifications such as amino acid isomerization or deamidation, methionine oxidation or asparagine or glutamine deamidation.
  • Monoclonal antibodies typically bind one antigenic epitope.
  • a bispecific monoclonal antibody binds two distinct antigenic epitopes.
  • Monoclonal antibodies may have heterogeneous glycosylation within the antibody population.
  • Monoclonal antibody may be monospecific or multispecific such as bispecific, monovalent, bivalent or multivalent.
  • Humanized antibody refers to an antibody in which at least one CDR is derived from non-human species and at least one framework is derived from human immunoglobulin sequences. Humanized antibody may include substitutions in the frameworks so that the frameworks may not be exact copies of expressed human immunoglobulin or human immunoglobulin germline gene sequences.
  • Human antibody refers to an antibody that is optimized to have minimal immune response when administered to a human subject. Variable regions of human antibody are derived from human immunoglobulin sequences. If human antibody contains a constant region or a portion of the constant region, the constant region is also derived from human immunoglobulin sequences. Human antibody comprises heavy and light chain variable regions that are“derived from” sequences of human origin if the variable regions of the human antibody are obtained from a system that uses human germline immunoglobulin or rearranged immunoglobulin genes.
  • Such exemplary systems are human immunoglobulin gene libraries displayed on phage, and transgenic non-human animals such as mice or rats carrying human immunoglobulin loci.
  • “Human antibody” typically contains amino acid differences when compared to the immunoglobulins expressed in humans due to differences between the systems used to obtain the human antibody and human immunoglobulin loci, introduction of somatic mutations or intentional introduction of substitutions into the frameworks or CDRs, or both.
  • “human antibody” is at least about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical in amino acid sequence to an amino acid sequence encoded by human germline immunoglobulin or rearranged immunoglobulin genes.
  • “human antibody” may contain consensus framework sequences derived from human framework sequence analyses, for example as described in Knappik et al., (2000) J Mol Biol 296:57-86, or a synthetic HCDR3 incorporated into human immunoglobulin gene libraries displayed on phage, for example as described in Shi et al., (2010) J Mol Biol 397:385-96, and in Int. Patent Publ. No. W02009/085462. Antibodies in which at least one CDR is derived from a non-human species are not included in the definition of“human antibody”.
  • “Alternative scaffold” refers to a single chain protein framework that contains a structured core associated with variable domains of high conformational tolerance.
  • the variable domains tolerate variation to be introduced without compromising scaffold integrity, and hence the variable domains can be engineered and selected for binding to a specific antigen.
  • Chimeric antigen receptor“ or“CAR” refers to engineered T cell receptors which graft a ligand or antigen specificity onto T cells (for example naive T cells central memory T cells effector memory T cells or combinations thereof). CARs are also known as artificial T- cell receptors, chimeric T-cell receptors or chimeric immunoreceptors. CARs comprise an extracellular domain capable of binding to an antigen, a transmembrane domain and at least one intracellular domain. CAR intracellular domain comprises a polypeptide known to function as a domain that transmits a signal to cause activation or inhibition of a biological process in a cell.
  • the transmembrane domain comprises any peptide or polypeptide known to span the cell membrane and that can function to link the extracellular and signaling domains.
  • a chimeric antigen receptor may optionally comprise a hinge domain which serves as a linker between the extracellular and transmembrane domains.
  • T cell receptor refers to a molecule capable of recognizing a peptide when presented by an MHC molecule.
  • Naturally -occurring TCR heterodimer consists of an alpha (a) and beta (b) chain in around 95% of T-cells, whereas around 5% of T-cells have TCRs consisting of gamma (g) and delta (5) chains.
  • Each chain of a natural TCR is a member of the immunoglobulin superfamily and possesses one N-terminal immunoglobulin (Ig)-variable (V) domain, one Ig-constant (C) domain, a transmembrane/cell membrane-spanning region, and a short cytoplasmic tail at the C- terminal end.
  • the variable domain of both the TCR a chain and b chain have three hypervariable or complementarity determining regions (CDRs), CDR1, CDR2 and CDR3, which are responsible for recognizing processed antigens presented on MHC.
  • TCR may be a full length a/b or g/d heterodimer or a soluble molecule comprising a portion of the extracellular domain of the TCR that retains binding the peptide/MHC complex.
  • TCR may be engineered into a single chain TCR.
  • T cell receptor complex or“TCR complex” refers to a known TCR complex comprising of a TCRa and TCRp chains, CD3rford CD3-/. CD35 and CD.32 molecules. In some instances, TCRa and TCRp chains are replaced by TCR / and TCR5 chains.
  • the amino acid sequences of the various proteins forming the TCR complex are well-known.
  • T cell and“T lymphocyte” are interchangeable and used synonymously herein.
  • T cell includes thymocytes, naive T lymphocytes, memory T cells, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes.
  • a T cell can be a T helper (Th) cell, for example a T helper 1 (Thl) or a T helper 2 (Th2) cell.
  • Th T helper 1
  • Th2 T helper 2
  • the T cell can be a helper T cell (HTL; CD4 + T cell) CD4 + T cell, a cytotoxic T cell (CTL; CD8 + T cell), a tumor infiltrating cytotoxic T cell (TIL; CD8 + T cell), CD4 + CD8 + T cell, or any other subset of T cells.
  • helper T cell CD4 + T cell
  • CTL cytotoxic T cell
  • TIL tumor infiltrating cytotoxic T cell
  • CD4 + CD8 + T cell CD4 + CD8 + T cell, or any other subset of T cells.
  • “NKT cells” refer to a specialized population of T cells that express a semiinvariant ab T-cell receptor, but also express a variety of molecular markers that are typically associated with NK cells, such as NK 1.1.
  • NKT cells include NK 1.1 + and NK 1. G, as well as CD4 + , CD4 , CD8 + and CD8 cells.
  • the TCR on NKT cells is unique in that it recognizes glycolipid antigens presented by the MHC I-like molecule CD Id. NKT cells can have either protective or deleterious effects due to their abilities to produce cytokines that promote either inflammation or immune tolerance. Also included are“gamma-delta T cells (gd T cells),” which refer to a specialized population that to a small subset of T cells possessing a distinct TCR on their surface, and unlike the majority of T cells in which the TCR is composed of two glycoprotein chains designated a- and b-TCR chains, the TCR in gd T cells is made up of a g- chain and a d-chain .
  • gd T cells gamma-delta T cells
  • gd T cells can play a role in immunosurveillance and immunoregulation, and were found to be an important source of IL-17 and to induce robust CD8 + cytotoxic T cell response. Also included are“regulatory T cells” or“Tregs” which refer to T cells that suppress an abnormal or excessive immune response and play a role in immune tolerance. Tregs are typically transcription factor Foxp3 -positive CD4 + T cells and can also include transcription factor Foxp3 -negative regulatory T cells that are IL-10-producing CD4 + T cells.
  • NK cell refers to a differentiated lymphocyte with a CD 16 + CD56 + and/or CD57 + TCR phenotype. NKs are characterized by their ability to bind to and kill cells that fail to express“self’ MHC/HLA antigens by the activation of specific cytolytic enzymes, the ability to kill tumor cells or other diseased cells that express a ligand for NK activating receptors, and the ability to release protein molecules called cytokines that stimulate or inhibit the immune response.
  • “About” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system. Unless explicitly stated otherwise within the Examples or elsewhere in the Specification in the context of a particular assay, result or embodiment,“about” means within one standard deviation per the practice in the art, or a range of up to 5%, whichever is larger.
  • Antigen presenting cell refers to any cell that presents on its surface an antigen in association with a major histocompatibility complex molecule, either MHC class I or MHC class II molecule, or both.
  • Prime-boost or“prime-boost regimen” refers to a method of treating a subject involving priming a T-cell response with a first vaccine followed by boosting the immune response with a second vaccine.
  • the first vaccine and the second vaccine are typically distinct.
  • These prime-boost immunizations elicit immune responses of greater height and breadth than can be achieved by priming and boosting with the same vaccine.
  • the priming step initiates memory cells and the boost step expands the memory response. Boosting can occur once or multiple times.
  • “Facilitator element” refers to any polynucleotide or polypeptide element that is operably linked to a polynucleotide or a polypeptide, and include promoters, enhancers, polyadenylation signals, stop codons, protein tags, such as histidine tag, and the like.
  • Facilitator elements herein include regulatory elements.
  • Distinct in the context of polypeptide or polynucleotide sequences refers to polypeptide or polynucleotide sequences that are not identical.
  • the disclosure relates to prostate neoantigens, polynucleotides encoding them, vectors, host cells, vaccines comprising the neoantigens or polynucleotides encoding the neoantigens, proteinaceous molecules binding the prostate neoantigens, and methods of making and using them.
  • the disclosure also provides vaccines comprising the prostate neoantigens of the disclosure that are prevalent in a population of prostate cancer patients, thereby providing a panvaccine that may be useful to treating a broad population of patients having diagnosed with various stages of prostate cancer, such as localized or metastasized prostate cancer.
  • Cancer cells produce neoantigens that result from genomic alterations and
  • Neoantigen burden in patients has been associated with response to immunotherapy (Snyder et ak, N Engl J Med. 2014 Dec 4;371(23):2189-2199. doi:
  • the disclosure is based, at least in part, on the identification of prostate neoantigens that are common in prostate cancer patients and hence can be utilized to develop a therapy amenable to treatment of a spectrum of prostate cancer patients.
  • One or more neoantigens or polynucleotides encoding the neoantigens of the disclosure may also be used for diagnostic or prognostic purposes.
  • Polypeptides and polynucleotides of the disclosure may also be used for diagnostic or prognostic purposes.
  • the disclosure provides an isolated polynucleotide encoding a polypeptide of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173, 175, 177,
  • the disclosure also provides an isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160, 162, 164, 166, 168, 170,
  • the disclosure also provides an isolated polynucleotide comprising a polynucleotide sequence of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491,
  • the fragments comprise at least 18 nucleotides. In some embodiments, the fragments comprise at least 21 nucleotides. In some embodiments, the fragments comprise at least 24 nucleotides. In some embodiments, the fragments comprise at least 27 nucleotides. In some embodiments, the fragments comprise at least 30 nucleotides. In some embodiments, the fragments comprise at least 33 nucleotides. In some embodiments, the fragments comprise at least 36 nucleotides. In some embodiments, the fragments comprise at least 39 nucleotides.
  • the fragments comprise at least 42 nucleotides. In some embodiments, the fragments comprise at least 45 nucleotides. In some embodiments, the fragments comprise at least 48 nucleotides. In some embodiments, the fragments comprise at least 51 nucleotides. In some embodiments, the fragments comprise at least 54 nucleotides. In some embodiments, the fragments comprise at least 57 nucleotides. In some embodiments, the fragments comprise at least 60 nucleotides. In some embodiments, the fragments comprise at least 63 nucleotides. In some embodiments, the fragments comprise at least 66 nucleotides. In some embodiments, the fragments comprise at least 69 nucleotides.
  • the fragments comprise at least 72 nucleotides. In some embodiments, the fragments comprise at least 75 nucleotides. In some embodiments, the fragments comprise about 18 nucleotides. In some embodiments, the fragments comprise about 21 nucleotides. In some embodiments, the fragments comprise about 24 nucleotides. In some embodiments, the fragments comprise about 27 nucleotides. In some embodiments, the fragments comprise about 30 nucleotides. In some embodiments, the fragments comprise about 33 nucleotides. In some embodiments, the fragments comprise about 36 nucleotides. In some embodiments, the fragments comprise about 39 nucleotides. In some embodiments, the fragments comprise about 42 nucleotides.
  • the fragments comprise about 45 nucleotides. In some embodiments, the fragments comprise about 48 nucleotides. In some embodiments, the fragments comprise about 51 nucleotides. In some embodiments, the fragments comprise about 54 nucleotides. In some embodiments, the fragments comprise about 57 nucleotides. In some embodiments, the fragments comprise about 60 nucleotides. In some embodiments, the fragments comprise about 63 nucleotides. In some embodiments, the fragments comprise about 66 nucleotides. In some embodiments, the fragments comprise about 69 nucleotides. In some embodiments, the fragments comprise about 72 nucleotides. In some embodiments, the fragments comprise about 75 nucleotides.
  • the fragments comprise about 18-75 nucleotides. In some embodiments, the fragments comprise about 21-75 nucleotides. In some embodiments, the fragments comprise about 24-75 nucleotides. In some embodiments, the fragments comprise about 24-72 nucleotides. In some embodiments, the fragments comprise about 24-69 nucleotides. In some embodiments, the fragments comprise about 24-66 nucleotides. In some embodiments, the fragments comprise about 24-63 nucleotides. In some embodiments, the fragments comprise about 24-60 nucleotides. In some embodiments, the fragments comprise about 24-57 nucleotides. In some embodiments, the fragments comprise about 24-54 nucleotides.
  • the fragments comprise about 24-51 nucleotides. In some embodiments, the fragments comprise about 24-48 nucleotides. In some embodiments, the fragments comprise about 24-45 nucleotides. In some embodiments, the fragments comprise about 24-42 nucleotides. In some embodiments, the fragments comprise about 27-42 nucleotides. In some embodiments, the fragments comprise about 27-39 nucleotides. In some embodiments, the fragments comprise about 27-36 nucleotides. In some embodiments, the fragments comprise about 27-33 nucleotides. In some embodiments, the fragments comprise about 27-30 nucleotides.
  • the polynucleotides and the heterologous polynucleotides of the disclosure encode the prostate neoantigens and heterologous polypeptides comprising two or more prostate neoantigens described herein.
  • the polynucleotides and the heterologous polynucleotides of the disclosure are useful in generating the polypeptides, the heterologous polypeptides, the vectors, the recombinant viruses, the cells and the vaccines of the disclosure.
  • the polynucleotides and the heterologous polynucleotides of the disclosure may be utilized as therapeutics by delivering them to a subject having a prostate cancer using various technologies, including viral vectors as described herein or other delivery technologies as also described herein.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 1 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 1, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 2 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 3 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 3, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 4 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 5 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 5, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 6 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 7 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 7, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 8 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 9 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 9, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 10 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 11 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 11, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 12 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 13 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 13, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 14 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 15 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 15, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 16 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 17 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 17, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 18 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 19 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 19, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 20 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 19, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 497 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 19, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 538 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 21 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 21, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 22 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 23 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 23, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 24 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 23, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 498 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 23, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 539 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 25 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 25, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 26 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 27 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 27, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 28 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 29 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 29, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 30 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 31 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 31, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 32 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 33 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 33, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 34 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 35 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 35, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 36 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 37 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 37, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 38 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 39 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 39, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 40 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 41 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 41, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 42 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 43 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 43, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 44 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 45 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 45, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 46 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 47 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 47, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 48 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 49 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 49, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 50 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 51 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 51, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 52 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 53 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 53, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 54 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 55 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 55, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 56 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 57 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 57, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 58 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 59 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 59, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 60 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 61 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 61, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 62 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 63 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 63, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 64 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 65 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 65, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 66 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 67 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 67, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 68 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 69 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 69, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 70 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 71 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 71, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 72 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 73 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 73, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 74 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 75 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 75, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 76 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 77 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 77, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 78 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 79 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 79, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 80 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 81 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 81, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 82 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 83 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 83, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 84 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 85 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 85, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 86 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 87 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 87, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 88 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 89 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 89, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 90 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 91 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 91, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 92 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 93 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 93, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 94 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 95 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 95, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 96 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 97 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 97, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 98 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 99 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 99, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 100 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 101 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 101, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 102 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 103 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 103, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 104 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 105 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 105, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 106 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 107 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 107, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 108 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 109 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 109, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 110 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 111 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 111, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 112 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 113 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 113, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 114 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 115 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 115, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 116 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 117 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 117, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 118 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 119 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 119, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 120 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 121 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 121, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 122 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 123 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 123, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 124 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 125 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 125, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 126 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 127 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 127, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 128 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 129 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 129, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 130 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 131 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 131, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 132 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 133 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 133, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 134 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 135 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 135, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 136 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 137 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 137, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 138 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 139 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 139, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 140 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 141 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 141, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 142 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 143 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 143, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 144 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 145 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 145, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 146 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 147 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 147, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 148 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 149 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 149, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 150 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 151 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 151, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 152 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 153 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 153, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 154 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 155 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 155, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 156 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 157 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 157, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 158 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 159 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 159, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 160 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 161 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 161, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 162 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 163 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 163, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 164 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 165 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 165, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 166 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 167 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 167, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 168 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 167, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 495 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 167, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 536 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 169 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 169, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 170 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 171 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 171, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 172 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 171, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 496 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 171, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 537 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 173 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 173, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 174 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 175 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 175, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 176 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 177 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 177, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 178 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 177, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 499 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 177, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 540 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 179 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 179, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 180 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 181 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 181, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 182 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 183 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 183, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 184 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 185 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 185, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 186 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 187 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 187, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 188 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 189 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 189, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 190 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 191 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 191, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 192 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 193 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 193, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 194 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 195 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 195, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 196 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 197 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 197, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 198 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 199 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 199, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 200 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 201 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 201, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 202 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 203 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 203, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 204 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 205 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 205, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 206 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 207 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 207, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 208 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 209 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 209, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 210 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 211 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 211, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 212 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 211, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 484 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 211, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 525 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 213 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 213, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 214 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 213, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 486 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 215 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 215, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 216 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 215, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 487 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 215, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 528 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 217 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 217, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 218 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 219 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 219, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 220 or a fragment thereof.
  • polypeptide of SEQ ID NO: 219, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 489 or a fragment thereof. In some embodiments, the polypeptide of SEQ ID NO: 219, or a fragment thereof, is encoded by the polynucleotide of SEQ ID NO: 530 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 221 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 221, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 222 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 221, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 488 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 221, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 529 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 223 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 223, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 224 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 223, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 494 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 223, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 535 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 225 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 225, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 226 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 225, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 490 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 225, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 531 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 227 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 227, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 228 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 229 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 229, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 230 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 231 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 231, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 232 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 233 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 233, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 234 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 235 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 235, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 236 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 235, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 493 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 235, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 534 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 237 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 237, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 238 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 239 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 239, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 240 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 241 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 241, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 242 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 243 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 243, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 244 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 245 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 245, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 246 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 245, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 470 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 245, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 511 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 247 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 247, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 248 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 249 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 249, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 250 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 251 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 251, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 252 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 251, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 469 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 251, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 510 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 253 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 253, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 254 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 253, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 464 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 253, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 505 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 255 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 255, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 256 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 255, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 474 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 255, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 515 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 257 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 257, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 258 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 259 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 259, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 260 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 261 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 261, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 262 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 261, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 471 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 261, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 512 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 263 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 263, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 264 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 265 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 265, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 266 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 265, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 472 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 265, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 513 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 267 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 267, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 268 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 269 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 269, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 270 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 269, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 463 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 269, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 504 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 271 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 271, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 272 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 271, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 465 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 271, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 508 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 273 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 273, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 274 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 275 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 275, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 276 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 275, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 459 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 275, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 500 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 277 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 277, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 278 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 277, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 475 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 277, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 516 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 279 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 279, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 280 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 281 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 281, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 282 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 283 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 283, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 284 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 285 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 285, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 286 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 285, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 477 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 287 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 287, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 288 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 289 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 289, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 290 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 291 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 291, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 292 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 293 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 293, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 294 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 295 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 295, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 296 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 297 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 297, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 298 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 297, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 476 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 297, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 517 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 299 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 299, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 300 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 301 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 301, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 302 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 303 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 303, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 304 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 305 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 305, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 306 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 305, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 468 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 305, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 509 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 307 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 307, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 308 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 309 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 309, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 310 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 309, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 465 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 309, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 506 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 311 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 311, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 312 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 313 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 313, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 314 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 315 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 315, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 316 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 317 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 317, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 318 or a fragment thereof.
  • polypeptide of SEQ ID NO: 317, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 473 or a fragment thereof. In some embodiments, the polypeptide of SEQ ID NO: 317, or a fragment thereof, is encoded by the polynucleotide of SEQ ID NO: 514 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 319 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 319, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 320 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 321 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 321, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 322 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 323 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 323, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 324 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 325 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 325, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 326 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 325, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 466 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 325, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 507 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 327 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 327, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 328 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 329 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 329, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 330 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 331 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 331, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 332 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 333 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 333, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 334 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 333, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 461 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 335 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 335, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 336 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 337 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 337, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 338 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 337, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 462 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 337, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 503 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 339 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 339, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 340 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 341 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 341, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 342 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 343 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 343, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 344 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 343, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 483 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 343, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 524 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 345 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 345, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 346 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 345, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 491 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 345, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 532 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 347 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 347, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 348 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 349 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 349, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 350 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 349, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 485 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 351 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 351, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 352 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 353 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 353, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 354 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 353, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 492 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 353, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 533 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 355 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 355, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 356 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 357 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 357, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 358 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 359 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 359, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 360 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 361 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 361, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 362 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 363 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 363, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 364 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 365 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 365, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 366 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 367 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 367, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 368 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 369 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 369, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 370 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 371 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 371, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 372 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 373 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 373, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 374 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 375 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 375, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 376 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 379 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 379, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 380 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 379, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 482 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 379, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 523 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 381 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 381, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 382 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 381, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 460 or a fragment thereof..
  • polypeptide of SEQ ID NO: 381, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 501 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 383 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 383, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 384 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 385 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 385, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 386 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 387 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 388 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 389 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 390 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 391 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 392 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 393 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 394 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 395 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 396 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 397 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 398 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 399 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 400 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 401 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 402 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 403 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 404 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 405 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 406 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 407 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 408 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 426 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 427 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 428 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 429 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 430 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 431 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 432 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 433 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 434 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 435 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 436 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 437 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 437, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 448 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 437, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 478 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 437, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 519 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 438 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 438, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 449 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 439 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 439, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 450 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 439, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 479 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 439, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 520 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 440 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 440, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 451 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 441 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 441, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 452 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 442 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 442, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 453 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 442, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 480 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 442, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 521 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 443 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 443, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 454 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 444 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 444, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 455 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 444, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 481 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 444, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 522 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 445 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 445, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 456 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 446 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 446, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 457 or a fragment thereof.
  • the disclosure also provides an isolated polynucleotide encoding the polypeptide of SEQ ID NO: 447 or a fragment thereof.
  • the polypeptide of SEQ ID NO: 447, or a fragment thereof is encoded by the polynucleotide of SEQ ID NO: 458 or a fragment thereof.
  • the heterologous polynucleotide is an in-frame heterologous polynucleotide.
  • the disclosure also provides an isolated heterologous polynucleotide encoding a heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169,
  • the disclosure also provides an isolated heterologous polynucleotide encoding a heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof.
  • the disclosure also provides an isolated heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66,
  • the disclosure also provides an isolated heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450, 453, 455, 380, 344, 212, 350, 214, 216, 222, 220, 226, 346, 354, 236, 224, 168, 172, 20, 24 and 178, and fragments thereof.
  • the polynucleotides may be codon-optimized utilizing known methods.
  • a heterologous polynucleotide comprising at least one of the polynucleotides of SEQ ID NOs: 459, 460, 461, 462, 463, 464,
  • a heterologous polynucleotide comprising at least one of the polynucleotides of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522, 523, 524, 525, 485, 486,
  • 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539 or 540 may be used.
  • the disclosure also provides an isolated heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481,
  • the disclosure also provides an isolated heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522,
  • the isolated heterologous polynucleotide is an in-frame heterologous polynucleotide.
  • the fragments comprise about 6-24 amino acids in length.
  • the fragments comprise at least 6 amino acids. In some embodiments, the fragments comprise at least 7 amino acids In some embodiments, the fragments comprise at least 8 amino acids. In some embodiments, the fragments comprise at least 9 amino acids. In some embodiments, the fragments comprise at least 10 amino acids. In some embodiments, the fragments comprise at least 11 amino acids. In some embodiments, the fragments comprise at least 12 amino acids. In some embodiments, the fragments comprise at least 13 amino acids. In some embodiments, the fragments comprise at least 14 amino acids. In some embodiments, the fragments comprise at least 15 amino acids. In some embodiments, the fragments comprise at least 16 amino acids. In some embodiments, the fragments comprise at least 17 amino acids.
  • the fragments comprise at least 18 amino acids. In some embodiments, the fragments comprise at least 19 amino acids. In some embodiments, the fragments comprise at least 20 amino acids. In some embodiments, the fragments comprise at least 21 amino acids. In some embodiments, the fragments comprise at least 22 amino acids. In some embodiments, the fragments comprise at least 23 amino acids. In some embodiments, the fragments comprise at least 24 amino acids. In some embodiments, the fragments comprise at least 25 amino acids. In some embodiments, the fragments comprise about 6 amino acids. In some embodiments, the fragments comprise about 7 amino acids. In some embodiments, the fragments comprise about 8 amino acids. In some embodiments, the fragments comprise about 9 amino acids. In some embodiments, the fragments comprise about 10 amino acids.
  • the fragments comprise about 11 amino acids. In some embodiments, the fragments comprise about 12 amino acids. In some embodiments, the fragments comprise about 13 amino acids. In some embodiments, the fragments comprise about 14 amino acids. In some embodiments, the fragments comprise about 15 amino acids. In some embodiments, the fragments comprise about 16 amino acids. In some embodiments, the fragments comprise about 17 amino acids. In some embodiments, the fragments comprise about 18 amino acids. In some embodiments, the fragments comprise about 19 amino acids. In some embodiments, the fragments comprise about 20 amino acids. In some embodiments, the fragments comprise about 21 amino acids. In some embodiments, the fragments comprise about 22 amino acids. In some embodiments, the fragments comprise about 23 amino acids.
  • the fragments comprise about 24 amino acids. In some embodiments, the fragments comprise about 25 amino acids. In some embodiments, the fragments comprise about 6-25 amino acids. In some embodiments, the fragments comprise about 7-25 amino acids. In some embodiments, the fragments comprise about 8-25 amino acids. In some embodiments, the fragments comprise about 8-24 amino acids. In some embodiments, the fragments comprise about 8-23 amino acids. In some embodiments, the fragments comprise about 8-22 amino acids. In some embodiments, the fragments comprise about 8-21 amino acids. In some embodiments, the fragments comprise about 8-20 amino acids. In some embodiments, the fragments comprise about 8-19 amino acids. In some embodiments, the fragments comprise about 8-18 amino acids.
  • the fragments comprise about 8-17 amino acids. In some embodiments, the fragments comprise about 8-16 amino acids. In some embodiments, the fragments comprise about 8-15 amino acids. In some embodiments, the fragments comprise about 8-14 amino acids. In some embodiments, the fragments comprise about 9-14 amino acids. In some embodiments, the fragments comprise about 9-13 amino acids. In some embodiments, the fragments comprise about 9-12 amino acids. In some embodiments, the fragments comprise about 9-11 amino acids. In some embodiments, the fragments comprise about 9-10 amino acids.
  • the fragments comprise SEQ ID Nos: 387, 388, 389, 390, 391,
  • the fragments comprise SEQ ID NOs: 377, 378, 415,417, 418, 420, 502, 518, 526, 527, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 74, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786,
  • the fragments are immunogenic fragments.
  • Immunogenic fragments in general are peptides that activate T cells, for example those that induce cytotoxic T cells when presented on MHC. Methods for assessing activation of T cells and/or induction of cytotoxic T lymphocytes are well known.
  • PBMCs isolated from a prostate cancer patient are cultured in vitro in the presence of a test neoantigen or fragments thereof and IL-25. The cultures may be replenished periodically with IL-15 and IL-2 and cultured for an additional 12 days. On day 12, the cultures are re-stimulated with the test neoantigen or fragments thereof and the following day T cell activation may be assessed by measuring a percentage of IFN-GTNAoG CD8 + cells when compared to a control culture.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173,
  • polypeptide is encoded by a polynucleotide sequence of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50,
  • the polypeptide is encoded by a polynucleotide sequence of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498 or 499, or fragments thereof.
  • the polypeptide is encoded by a polynucleotide sequence of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522, 523, 524, 525, 485, 486, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539 or 540, or fragments thereof.
  • the polypeptides and the heterologous polypeptides of the disclosure comprise one or more prostate neoantigens described herein.
  • the polypeptides and the heterologous polypeptides of the disclosure are useful in generating the recombinant viruses, the cells and the vaccines of the disclosure and proteinaceous molecules that specifically bind the one or more prostate neoantigens of the disclosure or may be used directly as therapeutic agents by delivering them to a subject having a prostate cancer using various technologies.
  • the two or more neoantigens e.g. polypeptides
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 1 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 3 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 5 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 7 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 9 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 11 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 13 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 15 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 17 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 19 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 21 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 23 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 25 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 27 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 29 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 31 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 33 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 35 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 37 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 39 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 41 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 43 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 45 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 47 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 49 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 51 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 53 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 55 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 57 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 59 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 61 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 63 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 65 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 67 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 69 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 71 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 73 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 75 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 77 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 79 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 81 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 83 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 85 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 87 or fragments thereof
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 89 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 91 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 93 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 95 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 97 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 99 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 101 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 103 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 105 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 107 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 109 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 111 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 113 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 115 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 117 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 119 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 121 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 123 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 125 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 127 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 129 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 131 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 133 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 135 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 137 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 139 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 141 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 143 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 145 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 147 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 149 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 151 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 153 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 155 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 157 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 159 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 161 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 163 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 165 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 167 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 169 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 171 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 173 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 175 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 177 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 179 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 181 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 183 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 185 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 187 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 189 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 191 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 193 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 195 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 197 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 199 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 201 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 203 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 205 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 207 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 209 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 211 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 213 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 215 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 217 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 219 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 221 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 223 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 225 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 227 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 229 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 231 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 233 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 235 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 237 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 239 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 241 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 243 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 245 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 247 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 249 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 251 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 253 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 255 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 257 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 259 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 261 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 263 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 265 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 267 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 269 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 271 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 273 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 275 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 277 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 279 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 281 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 283 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 285 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 287 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 289 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 291 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 293 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 295 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 297 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 299 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 301 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 303 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 305 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 307 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 309 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 311 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 313 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 315 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 317 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 319 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 321 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 323 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 325 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 327 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 329 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 331 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 333 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 335 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 337 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 339 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 341 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 343 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 345 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 347 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 349 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 351 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 353 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 355 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 357 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 359 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 361 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 363 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 365 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 367 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 369 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 371 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 373 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 375 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 379 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 381 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 383 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 385 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 387 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 388 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 389 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 390 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 391 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 392 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 393 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 394 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 395 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 396 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 397 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 398 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 399 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 400 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 401 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 402 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 403 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 404 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 405 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 406 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 407 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 408 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 426 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 427 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 428 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 429 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 430 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 431 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 432 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 433 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 434 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 435 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 436 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 437 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 438 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 439 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 440 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 441 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 442 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 443 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 444 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 445 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 446 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 447 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 560 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 561 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 562 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 563 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 564 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 565 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 566 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 567 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 568 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 569 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 570 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 571 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 572 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 573 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 574 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 575 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 576 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 577 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 578 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 579 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 580 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 581 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 582 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 583 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 584 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 585 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 586 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 587 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 588 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 589 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 590 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 591 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 592 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 593 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 594 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 595 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 596 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 597 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 598 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 599 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 600 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 601 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO:602 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 603 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 604 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 605 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 606 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 607 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 608 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 609 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 610 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 611 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 612 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 613 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 614 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 615 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 616 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 617 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 618 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 619 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 620 or fragments thereof.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NO: 621 or fragments thereof.
  • the disclosure also provides an isolated heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15,
  • the heterologous polypeptide is encoded by two or more polynucleotides selected from the group consisting of 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136, 138, 140, 142, 144, 146, 148, 150, 152, 154, 156, 158, 160,
  • the fragments are about 6-25 amino acids in length, such as about 8-25 amino acids in length.
  • the fragments comprise polypeptides of SEQ ID NOs: 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407,
  • the fragments comprise polypeptides of SEQ ID NOs: 377, 378, 415,417, 418, 420, 502, 518, 526, 527, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 74, 755, 756, 757, 758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772, 773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 7
  • the disclosure also provides an isolated heterologous polypeptide comprising two or more polypeptides selected from the group consisting of SEQ ID NOs: 275, 381, 333, 337, 269, 253, 309, 325, 271, 305, 251, 245, 261, 265, 317, 255, 277, 297, 285, 437, 439, 442, 444, 379, 343, 211, 349, 213, 215, 221, 219, 225, 345, 353, 235, 223, 167, 171, 19, 23 and 177, and fragments thereof.
  • the heterologous polypeptide is encoded by a heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 276, 382, 334, 338, 270, 254, 310, 326, 272, 306, 252, 246, 262, 266, 318, 256, 278, 298, 286, 448, 450, 453, 455, 380, 344, 212, 350, 214, 216, 222, 220, 226, 346, 354, 236, 224, 168, 172, 20, 24 and 178, and fragments thereof.
  • the heterologous polypeptide is encoded by a heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472, 473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487, 488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498 and 499, and fragments thereof.
  • the heterologous polypeptide is encoded by a heterologous polynucleotide comprising two or more polynucleotides selected from the group consisting of SEQ ID NOs: 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522, 523, 524, 525, 485, 486, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539 and 540, and fragments thereof.
  • SEQ ID NOs 500, 501, 461, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 477, 519, 520, 521, 522, 523, 524, 525, 485, 486, 528, 529
  • variants may comprise one or more substitutions, deletions or insertions, as long as the variants retain or have improved characteristics (such as immunogenicity or stability) when compared to the parent.
  • sequence identity may be about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
  • variants are generated by conservative substitutions.
  • the identity is about 80%. In some embodiments, the identity is about 85%. In some embodiments, the identity is about 90%. In some embodiments, the identity is about 91%. In some embodiments, the identity is about 91%. In some embodiments, the identity is about 92%. In some embodiments, the identity is about 93%. In some embodiments, the identity is about 94%. In some embodiments, the identity is 94%. In some embodiments, the identity is about 95%. In some embodiments, the identity is about 96%. In some embodiments, the identity is about 97%. In some embodiments, the identity is about 98%. In some embodiments, the identity is about 99%.
  • variants may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 substitutions, deletions or insertions, as long as the variants retain or have improved characteristics (such as immunogenicity or stability) when compared to the parent.
  • the percent identity between two amino acid sequences may be determined using the algorithm of E. Meyers and W. Miller ( ComputAppl Biosci 4: 11-17 (1988)) which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weight residue table, a gap length penalty of 12 and a gap penalty of 4.
  • the percent identity between two amino acid sequences may be determined using the Needleman and Wunsch ( JMol Biol 48:444-453 (1970)) algorithm which has been incorporated into the GAP program in the GCG software package (available at
  • the variants of the polypeptides or the heterologous polypeptides or fragments thereof containing one ammo acid alteration generally retain similar tertiary structure and antigenicity relative to the parent.
  • the variant may also contain at least one amino acid alteration that causes the variant to have increased antigenicity, increased binding affinity to TCR or to antibody, or both.
  • the variants of the polypeptides or the heterologous polypeptides may also have improved ability to bind to a HLA molecule.
  • the variants of the disclosure may be engineered to contain conservative substitutions.
  • Conservative substitutions are herein defined as exchanges within one of the following five groups: Group 1-small aliphatic, nonpolar or slightly polar residues (Ala, Ser, Thr, Pro, Gly); Group 2-polar, negatively charged residues and their amides (Asp, Asn, Glu, Gin); Group 3- polar, positively charged residues (His, Arg, Lys); Group 4-large, aliphatic, nonpolar residues (Met, Leu, he, Val, Cys); and Group 5-large, aromatic residues (Phe, Tyr, Trp).
  • the variants of the disclosure may be engineered to contain less conservative substitutions, such as the replacement of one amino acid by another that has similar characteristics but is somewhat different in size, such as replacement of an alanine by an isoleucine residue.
  • the variants of the disclosure may also be engineered to contain highly nonconservative substitutions which may involve substituting an acidic amino acid for one that is polar, or even for one that is basic in character.
  • substitutions may involve structures other than the common L-amino acids.
  • D-amino and non-standard amino acids i.e., other than the common naturally occurring proteinogenic amino acids
  • substitution purposes may also be used for substitution purposes to produce variants with enhanced immunogenicity when compared to the parent.
  • substitutions at more than one position are found to result in polypeptides or heterologous polypeptides with substantially equivalent or greater immunogenicity, then combinations of those substitutions may be tested to determine if the combined substitutions result in additive or synergistic effects on the immunogenicity of the variant.
  • amino acid residues that do not substantially contribute to interactions with the TCR may be modified by replacement with other amino acid whose incorporation does not substantially affect T-cell reactivity and does not eliminate binding to the relevant MHC.
  • the amino acid residues that do not substantially contribute to interactions with the TCR may also be deleted as long as the deletion does not substantially affect T-cell reactivity and does not eliminate binding to the relevant MHC.
  • polypeptides or the heterologous polypeptides or fragments thereof or variants may be further modified to improve stability and/or binding to MHC molecules in order to elicit a stronger immune response.
  • Methods for such an optimization of a peptide sequence are well known in the art and include, for example, the introduction of reverse peptide bonds or non-peptide bonds.
  • a reverse peptide bond amino acid residues are not joined by peptide (— CO— NH— ) linkages but the peptide bond is reversed.
  • Such retro-inverso peptidomimetics may be made using methods known in the art. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains.
  • polypeptides or the heterologous polypeptides or fragments thereof, or variants of the disclosure may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance the stability, bioavailability, and/or affinity of the peptides.
  • additional chemical groups such as carbobenzoxyl, dansyl, or t-butyloxy carbonyl groups may be added to the amino terminus.
  • an acetyl group or a 9-fluorenylmethoxy -carbonyl group may be placed at the amino termini.
  • the hydrophobic group, t- butyloxy carbonyl, or an amido group may be added to the carboxy termini.
  • polypeptides or the heterologous polypeptides or fragments thereof, or variants of the disclosure may be synthesized to alter their steric configuration.
  • the D-isomer of one or more of the amino acid residues of the peptide may be used, rather than the usual L-isomer.
  • the polypeptides or the heterologous polypeptides or fragments thereof, or variants of the disclosure may be modified chemically by reacting specific amino acids either before or after synthesis of the polypeptides or the heterologous polypeptides or fragments thereof, or variants of the disclosure. Examples for such modifications are well known in the art and are summarized e.g. in R.
  • modification of e.g. arginyl residues in proteins is often based on the reaction of vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2- cyclohexanedione to form an adduct.
  • vicinal dicarbonyl compounds such as phenylglyoxal, 2,3-butanedione, and 1,2- cyclohexanedione to form an adduct.
  • Cysteine can be modified without concomitant modification of other nucleophilic sites such as lysine and histidine.
  • a large number of reagents are available for the modification of cysteine.
  • the websites of companies such as Sigma-Aldrich (http ://www_sigma-aldrich.com) provide information on specific reagents.
  • Disulfide bonds can be formed and oxidized during the heat treatment of biopharmaceuticals.
  • Woodward's Reagent K may be used to modify specific glutamic acid residues.
  • N-(3-(dimethylamino)propyl)-N'-ethylcarbodiimide can be used to form intra-molecular crosslinks between a lysine residue and a glutamic acid residue.
  • diethylpyrocarbonate is a reagent for the modification of histidyl residues in proteins. Histidine can also be modified using 4-hydroxy -2 -nonenal.
  • lysine residues and other a-amino groups are, for example, useful in binding of peptides to surfaces or the cross- linking of proteins/peptides.
  • Lysine is the site of attachment of poly(ethylene)glycol and the major site of modification in the glycosylation of proteins.
  • Methionine residues in proteins can be modified with e.g. iodoacetamide, bromoethylamine, and chloramine T. Tetranitro methane and N-acetylimidazole can be used for the modification of tyrosyl residues.
  • Cross-linking via the formation of dityrosine can be accomplished with hydrogen peroxide/copper ions.
  • the disclosure provides an isolated polypeptide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81,
  • the disclosure also provides an isolated polypeptide comprising a polypeptide sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 substitutions, deletions or insertions when compared to the polypeptide of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71,
  • the disclosure also provides an isolated polynucleotide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 74, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 96, 98, 100, 102, 104, 106, 108, 110, 112, 114, 116, 118, 120, 122, 124, 126, 128, 130, 132, 134, 136
  • the disclosure also provides an isolated polypeptide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 560, 561, 562, 563, 564, 565, 566,
  • the disclosure also provides an isolated polypeptide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 377, 378, 415,417, 418, 420, 502, 518, 526, 527, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742, 743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 74, 755, 756, 757, 758, 759, 760, 761, 762, 763,
  • 904 905, 906, 907, 908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922,
  • the disclosure also provides an isolated polypeptide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 541, 550, 554, 555, 556, 623 or 624.
  • the disclosure also provides an isolated polynucleotide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 542 or SEQ ID NO: 551.
  • the disclosure also provides an isolated polypeptide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 543, 552, 557, 558, 559, 625 or 626.
  • the disclosure also provides an isolated polynucleotide that is about 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polypeptide of SEQ ID NOs: 544 or SEQ ID NO: 553.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135,
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572,
  • polypeptide comprises one or more reverse peptide bonds.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 377, 378, 415,417, 418, 420, 502, 518, 526, 527, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738,
  • polypeptide comprises one or more reverse peptide bonds.
  • the disclosure also provides an isolated heterologous polypeptide comprising an amino acid sequence of SEQ ID NOs: 541, 550, 554, 555, 556, 623 or 624, wherein the heterologous polypeptide comprises one or more reverse peptide bonds.
  • the disclosure also provides an isolated heterologous polypeptide comprising an amino acid sequence of SEQ ID NOs: EQ ID NOs: 543, 552, 557, 558, 559, 625 or 626, wherein the heterologous polypeptide comprises one or more reverse peptide bonds.
  • the reverse peptide bond comprises NH— CO bond.
  • the reverse peptide bond comprises CH 2— NH,— CH 2 S— ,
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, 51, 53, 55, 57, 59, 61, 63, 65, 67, 69, 71, 73, 75, 77, 79, 81, 83, 85, 87, 89, 91, 93, 95, 97, 99, 101, 103, 105, 107, 109, 111, 113, 115, 117, 119, 121, 123, 125, 127, 129, 131, 133, 135, 137, 139, 141, 143, 145, 147, 149, 151, 153, 155, 157, 159, 161, 163, 165, 167, 169, 171, 173,
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397, 398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 560, 561, 562, 563, 564, 565, 566, 567, 568, 569, 570, 571, 572,
  • polypeptide comprises one or more chemical modifications.
  • the disclosure also provides an isolated polypeptide comprising an amino acid sequence of SEQ ID NOs: 377, 378, 415,417, 418, 420, 502, 518, 526, 527, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727, 728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738,

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/IB2020/050145 2019-01-10 2020-01-09 Prostate neoantigens and their uses Ceased WO2020144615A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP20701888.8A EP3908311A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
PH1/2021/551633A PH12021551633A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
PE2021001152A PE20211660A1 (es) 2019-01-10 2020-01-09 Neoantigenos prostaticos y sus usos
CA3126462A CA3126462A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
SG11202107274VA SG11202107274VA (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
AU2020207641A AU2020207641B2 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
CR20210370A CR20210370A (es) 2019-01-10 2020-01-09 Neoantígenos prostáticos y sus usos
MX2021008392A MX2021008392A (es) 2019-01-10 2020-01-09 Neoantígenos prostaticos y sus usos.
JP2021539906A JP7524197B2 (ja) 2019-01-10 2020-01-09 前立腺ネオ抗原及びその使用
EA202191919A EA202191919A1 (ru) 2019-10-11 2020-01-09 Неоантигены предстательной железы и их применение
BR112021013507A BR112021013507A2 (pt) 2019-01-10 2020-01-09 Neoantígenos da próstata e seus usos
CN202080020511.3A CN113573729A (zh) 2019-01-10 2020-01-09 前列腺新抗原及其用途
KR1020217025212A KR20210113655A (ko) 2019-01-10 2020-01-09 전립선 신생항원 및 이의 용도
IL284561A IL284561A (en) 2019-01-10 2021-07-01 Prostate neoantigens and their uses
JOP/2021/0186A JOP20210186A1 (ar) 2019-01-10 2021-07-08 مستضدات البروستاتا المستحدثة واستخداماتها
CONC2021/0010006A CO2021010006A2 (es) 2019-01-10 2021-07-28 Neoantígenos prostáticos y sus usos

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962790673P 2019-01-10 2019-01-10
US62/790,673 2019-01-10
US201962851273P 2019-05-22 2019-05-22
US62/851,273 2019-05-22
US201962883786P 2019-08-07 2019-08-07
US62/883,786 2019-08-07
US201962913969P 2019-10-11 2019-10-11
US62/913,969 2019-10-11

Publications (1)

Publication Number Publication Date
WO2020144615A1 true WO2020144615A1 (en) 2020-07-16

Family

ID=69191089

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2020/050145 Ceased WO2020144615A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses
PCT/IB2020/050144 Ceased WO2020144614A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/IB2020/050144 Ceased WO2020144614A1 (en) 2019-01-10 2020-01-09 Prostate neoantigens and their uses

Country Status (23)

Country Link
US (3) US11793843B2 (enExample)
EP (1) EP3908311A1 (enExample)
JP (1) JP7524197B2 (enExample)
KR (1) KR20210113655A (enExample)
CN (1) CN113573729A (enExample)
AU (1) AU2020207641B2 (enExample)
BR (1) BR112021013507A2 (enExample)
CA (1) CA3126462A1 (enExample)
CL (2) CL2021001835A1 (enExample)
CO (1) CO2021010006A2 (enExample)
CR (1) CR20210370A (enExample)
EC (1) ECSP21056536A (enExample)
IL (1) IL284561A (enExample)
JO (1) JOP20210186A1 (enExample)
MA (1) MA54693A (enExample)
MX (1) MX2021008392A (enExample)
PE (1) PE20211660A1 (enExample)
PH (1) PH12021551633A1 (enExample)
SA (1) SA521422495B1 (enExample)
SG (1) SG11202107274VA (enExample)
TW (1) TWI852977B (enExample)
UY (1) UY38542A (enExample)
WO (2) WO2020144615A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021161244A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Neoantigens expressed in ovarian cancer and their uses
WO2022009051A1 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US11793843B2 (en) 2019-01-10 2023-10-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2025109597A1 (en) * 2023-11-22 2025-05-30 Yeda Research And Development Co. Ltd. T cell receptors directed against androgen receptor mutation
US12692513B2 (en) 2020-07-06 2026-07-28 Janssen Biotech, Inc. Prostate neoantigens and their uses

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202144389A (zh) * 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
WO2022179568A1 (en) * 2021-02-25 2022-09-01 Westlake Therapeutics (Hangzhou) Co., Limited Neoantigenic peptide and its use for treating braf gene mutation related diseases
AU2022414274A1 (en) * 2021-12-16 2024-08-01 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof
WO2024112821A1 (en) * 2022-11-22 2024-05-30 Elixirgen Therapeutics, Inc. Antigens for cancer immunotherapy
WO2026096933A1 (en) * 2024-11-01 2026-05-07 Board Of Regents, The University Of Texas System T cell receptors targeting sf3b1 and methods of use thereof
CN120058898B (zh) * 2025-02-25 2025-08-29 北京医院 用于治疗或改善前列腺癌的新抗原多肽及其制备方法和应用

Citations (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US563536A (en) 1896-07-07 Bracket for swinging stages
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4772848A (en) 1986-12-16 1988-09-20 Leybold-Heraeus Gmbh Gas measuring chamber for paramagnetic measuring instruments
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1990004036A1 (en) 1988-10-12 1990-04-19 Medical Research Council Production of antibodies from transgenic animals
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
US5185146A (en) 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
WO1995001447A1 (fr) 1993-06-30 1995-01-12 Cohen Haguenauer Odile Vecteur retroviral pour le transfert et l'expression de genes a visee therapeutique, dans des cellules eucaryotes
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
WO1996002655A1 (fr) 1994-07-13 1996-02-01 Rhone-Poulenc Rorer S.A. Composition contenant des acides nucleiques, preparation et utilisations
WO1996017070A1 (fr) 1994-12-01 1996-06-06 Transgene S.A. Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
WO1996019240A1 (en) 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
WO1996027677A2 (en) 1995-03-07 1996-09-12 Canji, Inc. Method of purification of recombinant viral vectors containing a therapeutic gene
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO1996040964A2 (en) 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5595897A (en) 1994-04-28 1997-01-21 I.D.M. Immuno-Designed Molecules Polylysine conjugates
WO1997004119A1 (fr) 1995-07-24 1997-02-06 Transgene S.A. Vecteurs viraux et lignee pour la therapie genique
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
WO1998000524A1 (fr) 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
WO1998026048A1 (en) 1996-12-13 1998-06-18 Schering Corporation Methods for purifying viruses
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1998037916A1 (fr) 1997-02-28 1998-09-03 Transgene S.A. Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
EP0901463A1 (fr) 1997-02-10 1999-03-17 Transgene S.A. Composes glycerolipidiques utiles pour le transfert d'une substance active dans une cellule cible
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
EP0919627A2 (fr) 1993-05-28 1999-06-02 Transgene S.A. Adénovirus défectifs et lignées de complémentation correspondantes
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
WO1999045962A1 (en) 1998-03-13 1999-09-16 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US5972707A (en) 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
US5976551A (en) 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5994106A (en) 1994-06-10 1999-11-30 Genvec, Inc. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6025337A (en) 1994-06-27 2000-02-15 Johns Hopkins University Solid microparticles for gene delivery
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000070071A1 (en) 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US6197302B1 (en) 1996-07-18 2001-03-06 Children's Hospital Medical Center Method of stimulating T cells
US6207195B1 (en) 1997-06-13 2001-03-27 The Johns Hopkins University Therapeutic nanospheres
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6270772B1 (en) 1997-09-16 2001-08-07 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
EP1230354A2 (de) 1999-11-18 2002-08-14 CEVEC Pharmaceuticals GmbH Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren
US6440442B1 (en) 1998-06-29 2002-08-27 Hydromer, Inc. Hydrophilic polymer blends used for dry cow therapy
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6586410B1 (en) 1995-06-07 2003-07-01 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
US7074905B2 (en) 1997-10-29 2006-07-11 Altor Bioscience Corporation Soluble MHC complexes and methods of use thereof
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US7141656B2 (en) 1996-01-31 2006-11-28 Altor Bioscience Corporation MHC complexes and uses thereof
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US7329731B2 (en) 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
US20100028637A1 (en) 2005-06-22 2010-02-04 Sunjuet Deutschland Gmbh Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer
US7709226B2 (en) 2001-07-12 2010-05-04 Arrowsmith Technology Licensing Llc Method of humanizing antibodies by matching canonical structure types CDRs
WO2010086189A2 (en) 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US20100216708A1 (en) 2008-10-31 2010-08-26 Steven Jacobs Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses
US20100255056A1 (en) 2009-02-12 2010-10-07 Steven Jacobs Fibronectin Type III Domain Based Scaffold Compositions, Methods And Uses
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
US7871817B2 (en) 2002-09-24 2011-01-18 Johannes Gutenberg-Universitat Mainz Method for rational mutagenesis of α/β t-cell receptors and correspondingly mutated mdm2-protein specific α/β t-cell receptors
EP1882700B1 (en) 2006-07-25 2011-01-26 Prolmmune Limited Biotinylated MHC complexes and their uses
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012022811A1 (en) 2010-08-20 2012-02-23 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen xv trimerization domain
US20120093934A1 (en) 2010-09-29 2012-04-19 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
EP2061807B1 (en) 2006-08-03 2012-07-18 ProImmune Limited MHC oligomers, components thereof, and methods of making the same
US20120252742A1 (en) 2009-10-06 2012-10-04 Kranz David M Human Single-Chain T Cell Receptors
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
WO2013096291A2 (en) 2011-12-20 2013-06-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
EP1670823B1 (en) 2003-10-06 2013-10-02 ProImmune Limited Chimeric mhc protein and oligomer thereof for specific targeting
WO2013157954A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US20130289253A1 (en) 2010-10-01 2013-10-31 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
US8828379B2 (en) 2010-02-18 2014-09-09 Universitetet I Oslo Disulphide bond-stabilized functional soluble MHC class II heterodimers
US20140303356A1 (en) 2011-10-27 2014-10-09 Michael Gramer Production of heterodimeric proteins
US9079941B2 (en) 2005-01-25 2015-07-14 Het Nederlands Kanker Instituut Means and methods for breaking noncovalent binding interactions between molecules
US9133264B2 (en) 2006-07-13 2015-09-15 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch Epitope-tag surface expressed proteins and nucleic acids thereof
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
US20160130319A1 (en) 2013-06-26 2016-05-12 Yi Li High-stability t-cell receptor and preparation method and application thereof
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
US20170003288A1 (en) 2015-06-01 2017-01-05 California Institute Of Technology Compositions and methods for screening t cells with antigens for specific populations
WO2017015064A1 (en) 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Detection phenotyping and quantitation of cells with multimeric binding reagent
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US20170095544A1 (en) 2015-05-06 2017-04-06 Pedro Santamaria Nanoparticle compositions for sustained therapy
US9624292B2 (en) 2011-03-24 2017-04-18 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
US20170121409A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses
WO2017091905A1 (en) 2015-12-02 2017-06-08 Innovative Targeting Solutions Inc. Single variable domain t-cell receptors
US9750801B2 (en) 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
US9790256B2 (en) 2015-08-20 2017-10-17 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
US9884075B2 (en) 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
EP3286210A1 (en) 2015-04-20 2018-02-28 UCL Business Plc. T cell receptor
WO2018037085A1 (en) * 2016-08-26 2018-03-01 Immatics Biotechnologies Gmbh Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
US20180064803A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
US20180118849A1 (en) 2016-09-30 2018-05-03 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2018098362A1 (en) * 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens
US10035832B2 (en) 2013-10-23 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2019008111A1 (en) 2017-07-05 2019-01-10 Nouscom Ag AMINO ACID AND NUCLEIC ACID SEQUENCES OF ADENOVIRUS OF NON-HUMAN GREEN APES, VECTORS CONTAINING SAME, AND USES THEREOF
WO2019115816A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
WO2019135086A1 (en) 2018-01-06 2019-07-11 Emergex Vaccines Holding Limited Mhc class i associated peptides for prevention and treatment of multiple flavi virus
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
WO2019191780A1 (en) 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery

Family Cites Families (183)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US914623A (en) 1908-08-19 1909-03-09 Henry H Williams Process in the manufacture of generating-plates for x-ray machines.
US1051266A (en) 1910-09-26 1913-01-21 George I Rockwood Apparatus for operating alarms or other devices.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5635363A (en) 1995-02-28 1997-06-03 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for the detection, quantitation and purification of antigen-specific T cells
CA2388301C (en) 1999-10-22 2011-01-04 Aventis Pasteur Limited Modified gp100 and uses thereof
US20030198953A1 (en) 2000-03-30 2003-10-23 Spytek Kimberly A. Novel proteins and nucleic acids encoding same
US20020192763A1 (en) * 2000-04-17 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
HU230198B1 (hu) 2000-11-23 2015-10-28 Bavarian Nordic A/S Módosított Vacciniavírus Ankara-variáns
JP2005519606A (ja) 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
EP1420822B2 (en) 2002-04-19 2017-07-05 Bavarian Nordic A/S Modified vaccinia virus ankara for the vaccination of neonates
KR101114784B1 (ko) 2002-11-12 2012-02-27 예일 유니버시티 아데노바이러스 벡터 백신
WO2004113571A2 (en) 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
WO2005046621A2 (en) 2003-11-12 2005-05-26 The United States Of America As Represented By The Secretary Of The Navy Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
EP1687334B1 (en) 2003-11-24 2014-01-08 MicroVAX, LLC Mucin antigen vaccine
US20050244851A1 (en) 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
AU2005308594A1 (en) 2004-11-24 2006-06-01 St George's Enterprises Limited Diagnosis of prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US7910565B2 (en) 2006-09-01 2011-03-22 Wisconsin Alumni Research Foundation Prostate cancer vaccine
NZ575388A (en) 2006-10-06 2012-03-30 Bn Immunotherapeutics Inc Recombinant modified vaccinia ankara encoding a her-2 antigen and a taxane for use in treating cancer
WO2008106615A1 (en) 2007-02-28 2008-09-04 Numenta, Inc. Spatio-temporal learning algorithms in hierarchical temporal networks
ES2725450T3 (es) 2007-07-02 2019-09-24 Etubics Corp Métodos y composiciones para la producción de un vector adenoviral para su uso en vacunaciones múltiples
ES2608604T3 (es) 2007-10-18 2017-04-12 Bavarian Nordic A/S Uso de MVA para tratar el cáncer de próstata
DK2212345T3 (en) 2007-11-19 2016-03-21 Transgene Sa Oncolytic poxvirus vectors
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2009111738A2 (en) 2008-03-06 2009-09-11 Mayo Foundation For Medical Education And Research Single cycle replicating adenovirus vectors
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
EP3062106B1 (en) 2008-04-16 2020-11-11 The Johns Hopkins University Method for determining androgen receptor variants in prostate cancer
US8685660B2 (en) 2008-09-03 2014-04-01 The Johns Hopkins University Genetic alterations in isocitrate dehydrogenase and other genes in malignant glioma
US8133724B2 (en) 2008-09-17 2012-03-13 University Of Maryland, Baltimore Human androgen receptor alternative splice variants as biomarkers and therapeutic targets
EP2774985B1 (en) 2008-10-31 2016-12-14 The Trustees Of The University Of Pennsylvania Simian adenovirus SAdV-43 and uses thereof
AU2010203517B2 (en) 2009-01-09 2012-08-16 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
US8394385B2 (en) 2009-03-13 2013-03-12 Bavarian Nordic A/S Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines
AU2010248761B2 (en) 2009-05-15 2016-02-11 Irx Therapeutics, Inc. Vaccine immunotherapy
EP2451475A2 (en) 2009-07-06 2012-05-16 Novartis AG Self replicating rna molecules and uses thereof
SI2506857T1 (en) 2009-12-01 2018-08-31 Translate Bio, Inc. Delivery of mRNA for the enrichment of proteins and enzymes in human genetic diseases
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
PT3243526T (pt) 2010-07-06 2020-03-04 Glaxosmithkline Biologicals Sa Distribuição de arn para despoletar múltiplas vias imunitárias
FI4005592T3 (fi) 2010-07-06 2023-01-13 Virionin kaltaisia kuljetuspartikkeleita itsereplikoituville rna-molekyyleille
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
CN103153284B (zh) 2010-07-06 2015-11-25 诺华股份有限公司 含有其pKa值有利于RNA递送的脂质的脂质体
US10487332B2 (en) 2010-07-06 2019-11-26 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of RNA
JP5911870B2 (ja) 2010-08-31 2016-04-27 ノバルティス アーゲー 免疫原をコードするｒｎａの送達のためのｐｅｇ化リポソーム
RS63890B1 (sr) 2010-08-31 2023-02-28 Glaxosmithkline Biologicals Sa Mali lipozomi za isporuku rnk koja kodira imunogen
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
CN103874706B (zh) 2011-04-28 2016-06-08 贝勒医学院 在人类前列腺癌富集的作为生物标记物的再生嵌合rna
GB201108879D0 (en) 2011-05-25 2011-07-06 Isis Innovation Vector
JP2014522842A (ja) 2011-07-06 2014-09-08 ノバルティス アーゲー 免疫原性組み合わせ組成物およびその使用
RU2014104090A (ru) 2011-07-06 2015-08-20 Новартис Аг Липосомы с эффективным соотношением n:p для доставки молекул phk
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
PT2750707T (pt) 2011-08-31 2019-01-23 Glaxosmithkline Biologicals Sa Lipossomas peguilados para distribuição de arn que codifica imunogénio
CA2851251C (en) 2011-10-05 2023-09-12 Genvec, Inc. Simian (gorilla) adenovirus or adenoviral vectors and methods of use
BR112014008694A2 (pt) 2011-10-11 2017-06-20 Novartis Ag moléculas de ácido nucleico policistrônico recombinante
WO2013116778A2 (en) 2012-02-02 2013-08-08 Board Of Regents Immunogenic adenovirus
US20160078168A1 (en) 2012-02-13 2016-03-17 Splicingcodes.Com Fusion transcript detection methods and fusion transcripts identified thereby
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
ES2728782T3 (es) * 2012-05-25 2019-10-28 Univ California Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN
AU2013296919A1 (en) 2012-07-30 2015-01-22 Alex Wah Hin Yeung Cancer vaccine comprises tumor cells, an oncolytic virus vector and/or an immune checkpoint modulator
EP2892549A1 (en) 2012-09-04 2015-07-15 Bavarian Nordic A/S Methods and compositions for enhancing vaccine immune responses
AU2013351542B2 (en) 2012-11-28 2018-08-09 BioNTech SE Individualized vaccines for cancer
SG11201506052PA (en) 2013-02-22 2015-09-29 Curevac Gmbh Combination of vaccination and inhibition of the pd-1 pathway
US10350275B2 (en) 2013-09-21 2019-07-16 Advantagene, Inc. Methods of cytotoxic gene therapy to treat tumors
JP6535337B2 (ja) 2013-11-05 2019-06-26 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルスならびに免疫チェックポイント阻害剤のアンタゴニスト及び／またはアゴニストにより癌を治療するための組み合わせ療法
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
ES2895977T3 (es) 2013-11-28 2022-02-23 Bavarian Nordic As Composiciones y métodos de inducción de una respuesta inmunitaria mejorada usando vectores de poxvirus
US20170106065A1 (en) 2013-12-31 2017-04-20 Bavarian Nordic A/S Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist of TIM-3
SG11201605432RA (en) 2014-01-02 2016-07-28 Sloan Kettering Inst Cancer Determinants of cancer response to immunotherapy
EA035259B1 (ru) 2014-02-14 2020-05-21 Иммьюн Дизайн Корп. Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
WO2015143221A1 (en) 2014-03-19 2015-09-24 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
HRP20220070T1 (hr) 2014-04-23 2022-04-01 Modernatx, Inc. Cjepiva nukleinske kiseline
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
DK3142690T3 (da) 2014-05-13 2022-05-09 Bavarian Nordic As Kombinationsterapi til behandling af cancer med et rekombinant poxvirus, der eksprimerer et tumorantigen, og en immun-checkpointmolekyleantagonist eller -agonist
JP2017515859A (ja) 2014-05-15 2017-06-15 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体と他の抗癌剤の組み合わせを使用する肺癌の処置
US20170106067A1 (en) 2014-06-12 2017-04-20 The Johns Hopkins University Combinatorial immunotherapy for pancreatic cancer treatment
CA2960087C (en) 2014-09-26 2024-02-27 Bavarian Nordic A/S Methods and compositions for intra-nasal immunization with recombinant mva encoding flagellin
CA2975432A1 (en) 2015-02-13 2016-08-18 Transgene Sa Immunotherapeutic vaccine and antibody combination therapy
KR20180006916A (ko) 2015-04-17 2018-01-19 메모리얼 슬로안-케터링 캔서 센터 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
DK3294326T3 (da) 2015-05-15 2021-05-31 Curevac Ag Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
US10995140B2 (en) 2015-06-05 2021-05-04 H. Lee Moffitt Cancer Center And Research Institute, Inc. GM-CSF/CD40L vaccine and checkpoint inhibitor combination therapy
EP3310384A1 (en) 2015-06-17 2018-04-25 CureVac AG Vaccine composition
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
GB201511191D0 (en) 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
IL308735A (en) 2015-07-01 2024-01-01 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201511546D0 (en) 2015-07-01 2015-08-12 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP6954648B2 (ja) 2015-10-19 2021-10-27 シージー オンコロジー， インコーポレイテッド 併用療法による固形腫瘍又はリンパ系腫瘍の治療方法
EP3364949A4 (en) 2015-10-22 2019-07-31 ModernaTX, Inc. CANCER VACCINES
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
KR20180095511A (ko) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
JP2019512020A (ja) 2016-02-12 2019-05-09 マディソン ヴァクシーンズ インコーポレイテッド がんの治療
WO2017147554A2 (en) 2016-02-25 2017-08-31 Memorial Sloan-Kettering Cancer Center Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors
CN109152815B (zh) 2016-02-25 2022-10-18 纪念斯隆凯特琳癌症中心 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒
WO2017152042A2 (en) 2016-03-04 2017-09-08 New York University Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity
WO2017162266A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Rna replicon for versatile and efficient gene expression
SG11201808196UA (en) 2016-03-31 2018-10-30 Neon Therapeutics Inc Neoantigens and methods of their use
WO2017177207A1 (en) 2016-04-07 2017-10-12 Bostongene, Llc Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
US20180126003A1 (en) 2016-05-04 2018-05-10 Curevac Ag New targets for rna therapeutics
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
RS63625B1 (sr) 2016-05-18 2022-10-31 Modernatx Inc Kombinacije irnk koje kodiraju imunomodulirajuće polipeptide i njihova upotreba
PL3458083T3 (pl) 2016-05-18 2023-03-13 Modernatx, Inc. Polinukleotydy kodujące interleukinę-12 (il12) i ich zastosowania
EP3735984A1 (en) 2016-05-27 2020-11-11 Etubics Corporation Neoepitope vaccine compositions and methods of use thereof
MX2018015542A (es) 2016-06-14 2019-10-14 Univ Pittsburgh Commonwealth Sys Higher Education Expresion de proteinas de ligando activadoras de nkg2d para la sensibilizacion de celulas cancerosas para el ataque por celulas inmunocitotoxicas.
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
EP3783032A1 (en) 2016-09-12 2021-02-24 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
AU2017336269B2 (en) 2016-09-28 2022-06-16 Bavarian Nordic A/S Compositions and methods for enhancing the stability of transgenes in poxviruses
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
WO2018102585A1 (en) * 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
JP7788787B2 (ja) 2016-12-05 2025-12-19 ヤンセン ファーマシューティカルズ，インコーポレーテッド 遺伝子発現増強のための組成物および方法
US11602554B2 (en) 2016-12-08 2023-03-14 City Of Hope P53-targeting vaccines and pd-1 pathway inhibitors and methods of use thereof
US10459372B2 (en) 2017-01-31 2019-10-29 Hewlett-Packard Development Company, L.P. Binary ink developer (BID) assembly for liquid electrophotography (LEP) printing device
CA3052255A1 (en) 2017-02-01 2018-08-09 Modernatx, Inc. Rna cancer vaccines
WO2018148381A1 (en) 2017-02-07 2018-08-16 Nantcell, Inc. Maximizing t-cell memory and compositions and methods therefor
CA3052290A1 (en) 2017-02-10 2018-08-16 The Rockefeller University Methods for cell-type specific profiling to identify drug targets
WO2018161092A1 (en) 2017-03-03 2018-09-07 New York University Induction and enhancement of antitumor immunity involving virus vectors expressing multiple epitopes of tumor associated antigens and immune checkpoint inhibitors or proteins
CA3050614A1 (en) 2017-03-17 2018-09-20 Curevac Ag Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy
EP3606550A2 (en) 2017-04-03 2020-02-12 Neon Therapeutics, Inc. Protein antigens and uses thereof
AU2018254526B2 (en) 2017-04-19 2024-02-15 Seattle Project Corp. Neoantigen identification, manufacture, and use
WO2018194890A1 (en) 2017-04-19 2018-10-25 University Of Iowa Research Foundation Cancer vaccines and methods of producing and using same
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
CN111107872A (zh) 2017-05-12 2020-05-05 纪念斯隆-凯特林癌症中心 有用于癌症免疫疗法的牛痘病毒突变体
CA3065327A1 (en) 2017-06-02 2018-12-06 Arizona Board Of Regents On Behalf Of Arizona State University Universal cancer vaccines and methods of making and using same
KR20240113607A (ko) 2017-06-21 2024-07-22 트랜스진 개인 맞춤형 백신
BR112020000590A2 (pt) * 2017-07-12 2020-07-14 Nouscom Ag método de seleção de uma coleção, métodos para determinar as sequências de aminoácidos e para produzir uma cvp ou uma coleção de ácidos nucleicos, cvp, coleções de peptídeos de vacina, de ácidos nucleicos, de um ou mais vetores de expressão e coleção de vetores de expressão
US20200230220A1 (en) 2017-07-12 2020-07-23 Nouscom Ag Neoantigen vaccine composition for treatment of cancer
WO2019023566A1 (en) 2017-07-28 2019-01-31 Janssen Vaccines & Prevention B.V. METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
GB201713163D0 (en) * 2017-08-16 2017-09-27 Univ Oxford Innovation Ltd HPV vaccine
IL272546B2 (en) 2017-08-24 2024-01-01 Bavarian Nordic As Combined therapy for the treatment of cancer with intravenous administration of recombinant MVA and antibody
US11839655B2 (en) 2017-09-01 2023-12-12 Microvax, Llc Combination cancer therapy
AU2018333530B2 (en) 2017-09-13 2024-05-30 Biontech Cell & Gene Therapies Gmbh RNA replicon for expressing a T cell receptor or an artificial T cell receptor
CN111670046B (zh) 2017-11-03 2024-11-08 Nouscom股份公司 疫苗的t细胞增强剂
WO2019094396A1 (en) 2017-11-07 2019-05-16 Nektar Therapeutics Immunotherapeutic combination for treating cancer
SG11202006457YA (en) 2018-01-05 2020-08-28 Ottawa Hospital Res Inst Modified orthopoxvirus vectors
BR112020013974A8 (pt) 2018-01-11 2022-10-18 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Ggmbh Formulação para administração de rna
US20210046130A1 (en) 2018-01-24 2021-02-18 Virogin Biotech Canada Ltd Recombinant viral vaccines
JP2021511060A (ja) 2018-01-26 2021-05-06 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
US20190367568A1 (en) 2018-02-05 2019-12-05 Nantbio, Inc. Calreticulin and fusion proteins
US11376290B2 (en) 2018-03-14 2022-07-05 Wuhan Boweid Biotechnology Co., Ltd. Recombinant oncolytic virus, synthetic DNA sequence, and application thereof
EP3773649A4 (en) 2018-03-28 2022-02-23 EpicentRx, Inc. PERSONALIZED CANCER VACCINE
TWI787500B (zh) 2018-04-23 2022-12-21 美商南特細胞公司 新抗原表位疫苗及免疫刺激組合物及方法
GB201807932D0 (en) 2018-05-16 2018-06-27 Redchenko Irina Compositions and methods for inducing an immune response
AU2019275070A1 (en) 2018-05-23 2021-01-14 Gritstone Bio, Inc. Immune checkpoint inhibitor co-expression vectors
TW202000907A (zh) 2018-05-23 2020-01-01 美商葛利史東腫瘤科技公司 共有抗原
CN118436618A (zh) 2018-05-30 2024-08-06 川斯勒佰尔公司 信使rna疫苗及其用途
WO2019238023A1 (en) * 2018-06-11 2019-12-19 Chineo Medical Technology Co., Ltd. Neoantigen vaccines and uses thereof
EP3587581A1 (en) 2018-06-26 2020-01-01 GlaxoSmithKline Biologicals S.A. Formulations for simian adenoviral vectors having enhanced storage stability
WO2020014539A1 (en) 2018-07-11 2020-01-16 Epicentrx, Inc. Methods and compositions for targeting cancer cells for treatment
WO2020022897A1 (en) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
GB201812647D0 (en) 2018-08-03 2018-09-19 Chancellor Masters And Scholars Of The Univ Of Oxford Viral vectors and methods for the prevention or treatment of cancer
CN113329761A (zh) 2018-09-04 2021-08-31 特雷斯生物有限公司 肽疫苗
CA3112654A1 (en) 2018-09-15 2020-03-19 Memorial Sloan Kettering Cancer Center Recombinant poxviruses for cancer immunotherapy
US12544433B2 (en) 2018-10-01 2026-02-10 The Wistar Institute Melanoma canine vaccine compositions and methods of use thereof
IL281988B2 (en) 2018-10-05 2025-03-01 Bavarian Nordic As Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
US20210369825A1 (en) 2018-10-05 2021-12-02 Nantcell, Inc. Cd40 and cd40l combo in an adv vaccine vehicle
US12576143B2 (en) 2018-10-19 2026-03-17 Nouscom Ag Teleost invariant chain cancer vaccine
MA54192A (fr) 2018-11-07 2021-09-15 Modernatx Inc Vaccins à arn contre le cancer
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
CN113424264B (zh) 2018-11-15 2024-04-12 Nouscom股份公司 用于生成个性化癌症疫苗的癌症突变选择
JP7625518B2 (ja) 2018-11-20 2025-02-03 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
JP2022512384A (ja) 2018-12-13 2022-02-03 ロード アイランド ホスピタル Ａｓｐｈ発現腫瘍の成長および進行の阻害
EP3893927A1 (en) 2018-12-14 2021-10-20 GlaxoSmithKline Biologicals S.A. Heterologous prime boost vaccine compositions and methods
WO2020131586A2 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Methods for identifying neoantigens
MX2021007446A (es) 2018-12-19 2021-09-08 United Biomedical Inc Epítopos artificiales promiscuos de linfocitos t colaboradores como estimuladores inmunes para inmunógenos peptídicos sintéticos.
CN109806390A (zh) 2019-01-07 2019-05-28 康希诺生物股份公司 一种SamRNA疫苗及其制备方法
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
CN115120716A (zh) 2019-01-14 2022-09-30 健泰科生物技术公司 用pd-1轴结合拮抗剂和rna疫苗治疗癌症的方法
AU2020210614A1 (en) 2019-01-21 2021-08-26 Sanofi Therapeutic RNA and anti-PD1 antibodies for advanced stage solid tumor cancers
TW202102543A (zh) 2019-03-29 2021-01-16 美商安進公司 溶瘤病毒在癌症新輔助療法中之用途
EP3721899A1 (en) 2019-04-08 2020-10-14 China Medical University Combination therapies comprising dendritic cells-based vaccine and immune checkpoint inhibitor
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
WO2020247547A1 (en) 2019-06-03 2020-12-10 Geovax, Inc. Cancer vaccine compositions and methods for use thereof
WO2022009049A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022009051A1 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
AU2022414274A1 (en) 2021-12-16 2024-08-01 Janssen Biotech, Inc. Prostate cancer vaccines and uses thereof

Patent Citations (164)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US563536A (en) 1896-07-07 Bracket for swinging stages
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4897445A (en) 1986-06-27 1990-01-30 The Administrators Of The Tulane Educational Fund Method for synthesizing a peptide containing a non-peptide bond
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
WO1988001649A1 (en) 1986-09-02 1988-03-10 Genex Corporation Single polypeptide chain binding molecules
US4772848A (en) 1986-12-16 1988-09-20 Leybold-Heraeus Gmbh Gas measuring chamber for paramagnetic measuring instruments
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5185146A (en) 1988-01-12 1993-02-09 Hoffmann-Laroche Inc. Recombinant mva vaccinia virus
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571698A (en) 1988-09-02 1996-11-05 Protein Engineering Corporation Directed evolution of novel binding proteins
US5403484A (en) 1988-09-02 1995-04-04 Protein Engineering Corporation Viruses expressing chimeric binding proteins
WO1990004036A1 (en) 1988-10-12 1990-04-19 Medical Research Council Production of antibodies from transgenic animals
US5744166A (en) 1989-02-25 1998-04-28 Danbiosyst Uk Limited Drug delivery compositions
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5580717A (en) 1990-05-01 1996-12-03 Affymax Technologies N.V. Recombinant library screening methods
WO1992001047A1 (en) 1990-07-10 1992-01-23 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5969108A (en) 1990-07-10 1999-10-19 Medical Research Council Methods for producing members of specific binding pairs
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5976551A (en) 1991-11-15 1999-11-02 Institut Pasteur And Institut Nationale De La Sante Et De La Recherche Medicale Altered major histocompatibility complex (MHC) determinant and method of using the determinant
US5734023A (en) 1991-11-19 1998-03-31 Anergen Inc. MHC class II β chain/peptide complexes useful in ameliorating deleterious immune responses
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6593081B1 (en) 1991-12-02 2003-07-15 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6582915B1 (en) 1991-12-02 2003-06-24 Medical Research Council Production of anti-self bodies from antibody segment repertories and displayed on phage
US6555313B1 (en) 1991-12-02 2003-04-29 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6544731B1 (en) 1991-12-02 2003-04-08 Medical Research Council Production of anti-self antibodies from antibody segment repertories and displayed on phage
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US6521404B1 (en) 1991-12-02 2003-02-18 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
WO1994013804A1 (en) 1992-12-04 1994-06-23 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5747323A (en) 1992-12-31 1998-05-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Retroviral vectors comprising a VL30-derived psi region
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6040174A (en) 1993-05-28 2000-03-21 Transgene S.A. Defective adenoviruses and corresponding complementation lines
EP0919627A2 (fr) 1993-05-28 1999-06-02 Transgene S.A. Adénovirus défectifs et lignées de complémentation correspondantes
WO1995001447A1 (fr) 1993-06-30 1995-01-12 Cohen Haguenauer Odile Vecteur retroviral pour le transfert et l'expression de genes a visee therapeutique, dans des cellules eucaryotes
US5820866A (en) 1994-03-04 1998-10-13 National Jewish Center For Immunology And Respiratory Medicine Product and process for T cell regulation
US5595897A (en) 1994-04-28 1997-01-21 I.D.M. Immuno-Designed Molecules Polylysine conjugates
US5994106A (en) 1994-06-10 1999-11-30 Genvec, Inc. Stocks of recombinant, replication-deficient adenovirus free of replication-competent adenovirus
US5851806A (en) 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5972707A (en) 1994-06-27 1999-10-26 The Johns Hopkins University Gene delivery system
US6025337A (en) 1994-06-27 2000-02-15 Johns Hopkins University Solid microparticles for gene delivery
WO1996002655A1 (fr) 1994-07-13 1996-02-01 Rhone-Poulenc Rorer S.A. Composition contenant des acides nucleiques, preparation et utilisations
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
US5559099A (en) 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
WO1996017070A1 (fr) 1994-12-01 1996-06-06 Transgene S.A. Procede de preparation d'un vecteur viral par recombinaison homologue intermoleculaire
WO1996019240A1 (en) 1994-12-21 1996-06-27 Novartis Ag Oligonucleotide-dendrimer conjugates
WO1996027011A1 (en) 1995-03-01 1996-09-06 Genentech, Inc. A method for making heteromultimeric polypeptides
WO1996027677A2 (en) 1995-03-07 1996-09-12 Canji, Inc. Method of purification of recombinant viral vectors containing a therapeutic gene
WO1996040964A2 (en) 1995-06-07 1996-12-19 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6586410B1 (en) 1995-06-07 2003-07-01 Inex Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5976567A (en) 1995-06-07 1999-11-02 Inex Pharmaceuticals Corp. Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US6534484B1 (en) 1995-06-07 2003-03-18 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5981501A (en) 1995-06-07 1999-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US6815432B2 (en) 1995-06-07 2004-11-09 Inex Pharmaceuticals Corp. Methods for encapsulating plasmids in lipid bilayers
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
WO1997004119A1 (fr) 1995-07-24 1997-02-06 Transgene S.A. Vecteurs viraux et lignee pour la therapie genique
US5837511A (en) 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5965541A (en) 1995-11-28 1999-10-12 Genvec, Inc. Vectors and methods for gene transfer to cells
US7141656B2 (en) 1996-01-31 2006-11-28 Altor Bioscience Corporation MHC complexes and uses thereof
WO1997035996A1 (en) 1996-03-25 1997-10-02 Transgene S.A. Packaging cell line based on human 293 cells
US5891690A (en) 1996-04-26 1999-04-06 Massie; Bernard Adenovirus E1-complementing cell lines
WO1998000524A1 (fr) 1996-07-01 1998-01-08 Rhone-Poulenc Rorer S.A. Procede de production d'adenovirus recombinants
US6197302B1 (en) 1996-07-18 2001-03-06 Children's Hospital Medical Center Method of stimulating T cells
US6348584B1 (en) 1996-10-17 2002-02-19 John Edward Hodgson Fibronectin binding protein compounds
WO1998026048A1 (en) 1996-12-13 1998-06-18 Schering Corporation Methods for purifying viruses
EP0901463A1 (fr) 1997-02-10 1999-03-17 Transgene S.A. Composes glycerolipidiques utiles pour le transfert d'une substance active dans une cellule cible
WO1998037916A1 (fr) 1997-02-28 1998-09-03 Transgene S.A. Nouveaux composes lipidiques et compositions les contenant utilisables pour le transfert d'au moins une substance active, notamment un polynucleotide, dans une cellule cible et utilisation en therapie genique
WO1998039411A1 (en) 1997-03-04 1998-09-11 Baxter International Inc. Adenovirus e1-complementing cell lines
WO1998044001A1 (en) 1997-03-27 1998-10-08 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US6673901B2 (en) 1997-06-12 2004-01-06 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US6207195B1 (en) 1997-06-13 2001-03-27 The Johns Hopkins University Therapeutic nanospheres
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US6270772B1 (en) 1997-09-16 2001-08-07 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US7074905B2 (en) 1997-10-29 2006-07-11 Altor Bioscience Corporation Soluble MHC complexes and methods of use thereof
WO1999045962A1 (en) 1998-03-13 1999-09-16 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5981225A (en) 1998-04-16 1999-11-09 Baylor College Of Medicine Gene transfer vector, recombinant adenovirus particles containing the same, method for producing the same and method of use of the same
US6113913A (en) 1998-06-26 2000-09-05 Genvec, Inc. Recombinant adenovirus
US6440442B1 (en) 1998-06-29 2002-08-27 Hydromer, Inc. Hydrophilic polymer blends used for dry cow therapy
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
WO2000050573A1 (fr) 1999-02-22 2000-08-31 Transgene S.A. Procede d'obtention d'une preparation virale purifiee
WO2000070071A1 (en) 1999-05-17 2000-11-23 Crucell Holland B.V. Adenovirus derived gene delivery vehicles comprising at least one element of adenovirus type 35
US7270811B2 (en) 1999-05-18 2007-09-18 Crucell Holland B.V. Serotype of adenovirus and uses thereof
EP1230354A2 (de) 1999-11-18 2002-08-14 CEVEC Pharmaceuticals GmbH Permanente amniozyten-zelllinie, ihre herstellung und verwendung zur herstellung von gentransfervektoren
WO2002043478A2 (en) 2000-11-30 2002-06-06 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
WO2002066630A1 (en) 2001-02-16 2002-08-29 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20150329617A1 (en) 2001-03-14 2015-11-19 Dynal Biotech Asa Novel MHC molecule constructs, and methods of employing these constructs for diagnosis and therapy, and uses of MHC molecules
WO2002088172A2 (en) 2001-04-30 2002-11-07 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7709226B2 (en) 2001-07-12 2010-05-04 Arrowsmith Technology Licensing Llc Method of humanizing antibodies by matching canonical structure types CDRs
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US7329731B2 (en) 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
US7871817B2 (en) 2002-09-24 2011-01-18 Johannes Gutenberg-Universitat Mainz Method for rational mutagenesis of α/β t-cell receptors and correspondingly mutated mdm2-protein specific α/β t-cell receptors
US7569664B2 (en) 2002-10-09 2009-08-04 Immunocore Limited Single chain recombinant T cell receptors
WO2005048957A2 (en) 2003-02-20 2005-06-02 Therion Biologics Corporation Novel insertion sites in pox vectors
US8377447B2 (en) 2003-09-05 2013-02-19 Oregon Health & Science University Monomeric recombinant MHC molecules useful for manipulation of antigen-specific T cells
EP1670823B1 (en) 2003-10-06 2013-10-02 ProImmune Limited Chimeric mhc protein and oligomer thereof for specific targeting
WO2005071093A2 (en) 2004-01-23 2005-08-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Chimpanzee adenovirus vaccine carriers
US9079941B2 (en) 2005-01-25 2015-07-14 Het Nederlands Kanker Instituut Means and methods for breaking noncovalent binding interactions between molecules
US20100015133A1 (en) 2005-03-31 2010-01-21 Chugai Seiyaku Kabushiki Kaisha Methods for Producing Polypeptides by Regulating Polypeptide Association
US20100028637A1 (en) 2005-06-22 2010-02-04 Sunjuet Deutschland Gmbh Multi-Layer Film Comprising a Barrier Layer and an Antistatic Layer
WO2007104792A2 (en) 2006-03-16 2007-09-20 Crucell Holland B.V. Recombinant adenoviruses based on serotype 26 and 48, and use thereof
US20070287170A1 (en) 2006-03-24 2007-12-13 Merck Patent Gmbh Engineered heterodimeric protein domains
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
US9133264B2 (en) 2006-07-13 2015-09-15 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) Berlin-Buch Epitope-tag surface expressed proteins and nucleic acids thereof
EP1882700B1 (en) 2006-07-25 2011-01-26 Prolmmune Limited Biotinylated MHC complexes and their uses
EP2061807B1 (en) 2006-08-03 2012-07-18 ProImmune Limited MHC oligomers, components thereof, and methods of making the same
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods
WO2009134776A2 (en) 2008-04-29 2009-11-05 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
US20100261620A1 (en) 2008-10-14 2010-10-14 Juan Carlos Almagro Methods of Humanizing and Affinity-Maturing Antibodies
US20100216708A1 (en) 2008-10-31 2010-08-26 Steven Jacobs Fibronectin Type III Domain Based Scaffold Compositions, Methods and Uses
WO2010086189A2 (en) 2009-02-02 2010-08-05 Okairòs Ag, Switzerland Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
US20100255056A1 (en) 2009-02-12 2010-10-07 Steven Jacobs Fibronectin Type III Domain Based Scaffold Compositions, Methods And Uses
US20110123532A1 (en) 2009-04-27 2011-05-26 Oncomed Pharmaceuticals, Inc. Method for Making Heteromultimeric Molecules
US20120252742A1 (en) 2009-10-06 2012-10-04 Kranz David M Human Single-Chain T Cell Receptors
US8828379B2 (en) 2010-02-18 2014-09-09 Universitetet I Oslo Disulphide bond-stabilized functional soluble MHC class II heterodimers
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
WO2011143545A1 (en) 2010-05-14 2011-11-17 Rinat Neuroscience Corporation Heterodimeric proteins and methods for producing and purifying them
WO2012022811A1 (en) 2010-08-20 2012-02-23 Leadartis, S.L. Engineering multifunctional and multivalent molecules with collagen xv trimerization domain
US20120093934A1 (en) 2010-09-29 2012-04-19 Uti Limited Partnership Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres
US20130289253A1 (en) 2010-10-01 2013-10-31 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
US20120149876A1 (en) 2010-11-05 2012-06-14 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
US9624292B2 (en) 2011-03-24 2017-04-18 Universitätsmedizin Der Johannes Gutenberg-Universität Mainz Single chain antigen recognizing constructs (scARCs) stabilized by the introduction of novel disulfide bonds
WO2012177624A2 (en) 2011-06-21 2012-12-27 The Johns Hopkins University Focused radiation for augmenting immune-based therapies against neoplasms
US20140303356A1 (en) 2011-10-27 2014-10-09 Michael Gramer Production of heterodimeric proteins
US20130195849A1 (en) 2011-11-04 2013-08-01 Zymeworks Inc. Stable Heterodimeric Antibody Design with Mutations in the Fc Domain
WO2013096291A2 (en) 2011-12-20 2013-06-27 Medimmune, Llc Modified polypeptides for bispecific antibody scaffolds
WO2013157954A1 (en) 2012-04-20 2013-10-24 Merus B.V. Methods and means for the production of ig-like molecules
US20160130319A1 (en) 2013-06-26 2016-05-12 Yi Li High-stability t-cell receptor and preparation method and application thereof
US10035832B2 (en) 2013-10-23 2018-07-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use
US9884075B2 (en) 2014-01-16 2018-02-06 California Institute Of Technology Domain-swap T cell receptors
US9750801B2 (en) 2014-02-28 2017-09-05 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
EP3286210A1 (en) 2015-04-20 2018-02-28 UCL Business Plc. T cell receptor
US20170095544A1 (en) 2015-05-06 2017-04-06 Pedro Santamaria Nanoparticle compositions for sustained therapy
WO2016187508A2 (en) * 2015-05-20 2016-11-24 The Broad Institute Inc. Shared neoantigens
US20170003288A1 (en) 2015-06-01 2017-01-05 California Institute Of Technology Compositions and methods for screening t cells with antigens for specific populations
WO2017015064A1 (en) 2015-07-20 2017-01-26 The Board Of Trustees Of The Leland Stanford Junior University Detection phenotyping and quantitation of cells with multimeric binding reagent
WO2017020026A1 (en) * 2015-07-30 2017-02-02 Modernatx, Inc. Concatemeric peptide epitopes rnas
US9790256B2 (en) 2015-08-20 2017-10-17 Janssen Vaccines & Prevention B.V. Therapeutic HPV18 vaccines
US20170121409A1 (en) 2015-11-03 2017-05-04 Janssen Biotech, Inc. Antibodies specifically binding pd-1, tim-3 or pd-1 and tim-3 and their uses
WO2017091905A1 (en) 2015-12-02 2017-06-08 Innovative Targeting Solutions Inc. Single variable domain t-cell receptors
WO2017180770A1 (en) 2016-04-13 2017-10-19 Synthetic Genomics, Inc. Recombinant arterivirus replicon systems and uses thereof
WO2017220499A1 (en) 2016-06-20 2017-12-28 Janssen Vaccines & Prevention B.V. Potent and balanced bidirectional promoter
WO2018037085A1 (en) * 2016-08-26 2018-03-01 Immatics Biotechnologies Gmbh Novel peptides and scaffolds for use in immunotherapy against head and neck squamous cell carcinoma and other cancers
US20180064803A1 (en) 2016-09-02 2018-03-08 Janssen Vaccines & Prevention B.V. Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
US20180118849A1 (en) 2016-09-30 2018-05-03 Hoffmann-La Roche Inc. Bispecific t cell activating antigen binding molecules
WO2018075235A1 (en) 2016-10-17 2018-04-26 Synthetic Genomics, Inc. Recombinant virus replicon systems and uses thereof
WO2018098362A1 (en) * 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens
WO2018146205A1 (en) 2017-02-09 2018-08-16 Janssen Vaccines & Prevention B.V. Potent and short promoter for expression of heterologous genes
WO2019008111A1 (en) 2017-07-05 2019-01-10 Nouscom Ag AMINO ACID AND NUCLEIC ACID SEQUENCES OF ADENOVIRUS OF NON-HUMAN GREEN APES, VECTORS CONTAINING SAME, AND USES THEREOF
WO2019115816A1 (en) 2017-12-15 2019-06-20 Glaxosmithkline Biologicals Sa Hepatitis b immunisation regimen and compositions
WO2019135086A1 (en) 2018-01-06 2019-07-11 Emergex Vaccines Holding Limited Mhc class i associated peptides for prevention and treatment of multiple flavi virus
WO2019143949A2 (en) 2018-01-19 2019-07-25 Synthetic Genomics, Inc. Induce and enhance immune responses using recombinant replicon systems
WO2019191780A1 (en) 2018-03-30 2019-10-03 Arcturus Therapeutics, Inc. Lipid particles for nucleic acid delivery

Non-Patent Citations (75)

* Cited by examiner, † Cited by third party
Title
"Cell", vol. 163, 5 November 2015, article "Cancer Genome Atlas Research Network", pages: 1011 - 25
"GenBank", Database accession no. DQ983237
AHL, BIOCHIM. BIOPHYS. ACTA, vol. 1329, 1997, pages 370 - 382
AKIMARU, CYTOKINES MOL. THER., vol. 1, 1995, pages 197 - 210
ALVING, IMMUNOL. REV., vol. 145, 1995, pages 5 - 31
ARMENIA ET AL., NAT GENET, vol. 50, no. 5, 2018, pages 645 - 651
ARMENIA ET AL., NAT GENET., vol. 50, no. 5, May 2018 (2018-05-01), pages 645 - 651
BAKKER, AH ET AL., PROC NATL ACAD SCI USA, vol. 105, 2008, pages 3825 - 30
BEHR ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 6982 - 6986
BRIIGGEMANNTAUSSIG, CURR OPIN BIOTECHNOL, vol. 8, 1997, pages 455 - 458
BRUGGEMANN ET AL., EUR J IMMUNOL, vol. 21, 1991, pages 1323 - 1326
CHOTHIA ET AL., J MOL BIOL, vol. 196, 1987, pages 901 - 17
DANOSMULLIGAN, PROC. NATL. ACAD. SCI. USA, vol. 85, 1988, pages 6460
E. MEYERSW. MILLER, COMPUTAPPL BIOSCI, vol. 4, 1988, pages 11 - 17
FEIGNER ET AL., METHODS, vol. 5, pages 67 - 75
FEIGNER ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 7413 - 7417
FISHWILD ET AL., NAT BIOTECHNOL, vol. 14, 1996, pages 845 - 851
GADI ET AL., GENE THER., vol. 7, 2000, pages 1738 - 1743
GAOHUANG, BBRC, vol. 179, 1991, pages 280 - 285
GE H ET AL., BIOINFORMATICS, vol. 27, no. 14, 15 July 2011 (2011-07-15), pages 1922 - 8
GILBOA ET AL., ADV. EXP. MED. BIOL., vol. 241, 1988, pages 29
GODING: "Monoclonal Antibodies: Principles and Practice", 1986, ACADEMIC PRESS, pages: 59 - 103
GRAHAM ET AL., J. GEN. VIROL., vol. 36, 1977, pages 59 - 72
GREEN ET AL., NATURE GENET., vol. 7, 1994, pages 13 - 21
GREEN, JLMMUNOL METHODS, vol. 231, 1999, pages 11 - 23
GREENJAKOBOVITS, EXP. MED., vol. 188, 1998, pages 483 - 95
HAENSLERSZOKA, BIOCONJUGATE CHEM., vol. 4, 1993, pages 372 - 379
HONEGGERPLUCKTHUN, J MOL BIOL, vol. 309, 2001, pages 657 - 70
HOOGENBOOMWINTER, J MOL BIOL, vol. 222, 1991, pages 581
HOSSE ET AL.: "A New Generation of Protein Display Scaffolds for Molecular Recognition", PROTEIN SCI., vol. 15, 2006, pages 14 - 27, XP002541836, DOI: 10.1110/ps.051817606
JULIANO, BIOCHEM. BIOPHYS. RES. COMMUN., vol. 63, 1975, pages 651
KNAPPIK ET AL., J MOL BIOL, vol. 296, 2000, pages 57 - 86
KOHLERMILSTEIN, NATURE, vol. 256, 1975, pages 495
KREBS ET AL., JLMMUNOL METH, vol. 254, 2001, pages 67 - 84
KROUGHAKGRAHAM, HUMAN GENE THER., vol. 6, 1995, pages 1575 - 1586
LE ET AL., N ENGL J MED., vol. 372, no. 26, 25 June 2015 (2015-06-25), pages 2509 - 20
LEFRANC ET AL., DEV COMP IMMUNOL, vol. 27, 2003, pages 55 - 77
LONBERG ET AL., NATURE, vol. 368, 1994, pages 856 - 9
LONBERGHUSZAR, INT REV IMMUNOL, vol. 13, 1995, pages 65 - 93
LOPATA ET AL., NUCLEIC ACID RES., vol. 12, 1984, pages 5707 - 5717
LUSKY ET AL., J. VIROL., vol. 72, 1998, pages 2022 - 203
MARKOWITZ ET AL., VIROL., vol. 167, 1988, pages 400
MARTINTHORNTON, J BMOL BIOL, vol. 263, 1996, pages 800 - 15
MAYR, A.DANNER, K.: "Vaccination against pox diseases under immunosuppressive conditions", DEV. BIOL. STAND., vol. 41, 1978, pages 225 - 34
MCLACHLAN ET AL., GENE THERAPY, vol. 2, 1995, pages 674 - 622
MEISINGER-HENSCHEL ET AL.: "Genomic sequence of chorioallantois vaccinia virus Ankara, the ancestor of modified vaccinia virus Ankara", J. GEN. VIROL., vol. 88, 2007, pages 3249 - 3259, XP002608124, DOI: 10.1099/VIR.0.83156-0
MENDEZ, NAT GENET, vol. 15, 1997, pages 146 - 156
MEYER ET AL., J. GEN. VIROL., vol. 72, 1991, pages 1031 - 8
MEYER, H. ET AL.: "Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence", J. GEN. VIROL., vol. 72, 1991, pages 1031 - 1038, XP000952390
MILLERROSMAN, BIOTECHNIQUES, vol. 7, 1989, pages 980
NEEDLEMANWUNSCH, J MOL BIOL, vol. 48, 1970, pages 444 - 453
NICAISE ET AL.: "Affinity Transfer by CDR Grafting on a Nonimmunoglobulin Scaffold", PROTEIN SCI., vol. 13, 2004, pages 1882 - 1891, XP009098876
NYGRENUHLEN: "Scaffolds for Engineering Novel Binding Sites in Proteins", CURR. OPIN. STRUC. BIOL., vol. 7, 1997, pages 463 - 469
PADLAN, MOL IMMUNOL, vol. 28, 1991, pages 489 - 499
PICCINI ET AL., METHODS OF ENZYMOLOGY, vol. 153, 1987, pages 545 - 563
RICARDO G CORREA ET AL: "The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling", ONCOTARGET, 26 March 2014 (2014-03-26), pages 1666 - 1682, XP055688954 *
RIZVI ET AL., SCIENCE, vol. 348, no. 6230, 3 April 2015 (2015-04-03), pages 124 - 8
ROBINSOND ET AL., CELL, vol. 161, no. 5, 21 May 2015 (2015-05-21), pages 1215 - 1228
RODENKO, B ET AL., NATURE PROTOCOLS, vol. 1, 2006, pages 1120 - 32
ROMANI ET AL., J. EXP. MED., vol. 169, 1989, pages 1169
SHEETS ET AL., PITAS (USA), vol. 95, 1998, pages 6157 - 6162
SHI ET AL., J MOL BIOL, vol. 397, 2010, pages 385 - 96
SKERRA, A.: "Alternative Non-Antibody Scaffolds for Molecular Recognition", CURR. OPIN. BIOTECHNOL., vol. 18, 2005, pages 295 - 304
SNYDER ET AL., N ENGL J MED., vol. 371, no. 23, 4 December 2014 (2014-12-04), pages 2189 - 2199
STEINMAN, ANNU. REV. IMMUNOL., vol. 9, 1991, pages 271
SUN ET AL., MOL MED REP., vol. 10, no. 5, 2014, pages 2657 - 2662
SZOKA, ANN. REV. BIOPHYS. BIOENG., vol. 9, 1980, pages 467
TOEBES, M ET AL., NAT MED, vol. 12, 2006, pages 246 - 51
VAN ALLEN ET AL., SCIENCE, vol. 350, no. 6257, 9 October 2015 (2015-10-09), pages 207 - 211
VAUGHAN ET AL., NATURE BIOTECHNOLOGY, vol. 14, 1996, pages 309 - 314
WANG ET AL., GENE THER., vol. 2, 1995, pages 775 - 783
WOYKE ET AL., ANTIMICROB AGENTS AND CHEMOTHER., vol. 45, no. 12, 2001, pages 3580 - 3584
WU ET AL., J EXP MED, vol. 132, 1970, pages 211 - 50
YANG ET AL., CANCER RES, vol. 59, 1999, pages 1236 - 1243
YEH ET AL., J. VIROL., vol. 70, 1996, pages 559 - 565

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11793843B2 (en) 2019-01-10 2023-10-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12582683B2 (en) 2019-01-10 2026-03-24 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2021161244A1 (en) * 2020-02-14 2021-08-19 Janssen Biotech, Inc. Neoantigens expressed in ovarian cancer and their uses
US11945881B2 (en) 2020-02-14 2024-04-02 Janssen Biotech, Inc. Neoantigens expressed in ovarian cancer and their uses
WO2022009051A1 (en) * 2020-07-06 2022-01-13 Janssen Biotech, Inc. A method for determining responsiveness to prostate cancer treatment
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
US12692513B2 (en) 2020-07-06 2026-07-28 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2025109597A1 (en) * 2023-11-22 2025-05-30 Yeda Research And Development Co. Ltd. T cell receptors directed against androgen receptor mutation

Also Published As

Publication number Publication date
PE20211660A1 (es) 2021-08-26
US11793843B2 (en) 2023-10-24
US12582683B2 (en) 2026-03-24
TW202043256A (zh) 2020-12-01
PH12021551633A1 (en) 2022-06-06
WO2020144614A1 (en) 2020-07-16
JP2022516770A (ja) 2022-03-02
US20200222478A1 (en) 2020-07-16
ECSP21056536A (es) 2023-02-28
SG11202107274VA (en) 2021-07-29
EP3908311A1 (en) 2021-11-17
JOP20210186A1 (ar) 2021-07-08
KR20210113655A (ko) 2021-09-16
CN113573729A (zh) 2021-10-29
MA54693A (fr) 2021-11-17
US20240139265A1 (en) 2024-05-02
SA521422495B1 (ar) 2024-02-05
UY38542A (es) 2020-07-31
AU2020207641A1 (en) 2021-07-22
CO2021010006A2 (es) 2021-08-30
JP7524197B2 (ja) 2024-07-29
AU2020207641B2 (en) 2026-06-11
CR20210370A (es) 2021-09-09
CL2021001835A1 (es) 2022-01-21
US20260207689A1 (en) 2026-07-23
CL2022000373A1 (es) 2022-10-28
CA3126462A1 (en) 2020-07-16
MX2021008392A (es) 2021-10-26
IL284561A (en) 2021-08-31
TWI852977B (zh) 2024-08-21
BR112021013507A2 (pt) 2021-11-16

Similar Documents

Publication Publication Date Title
US12582683B2 (en) Prostate neoantigens and their uses
CN112088008B (zh) 修饰细胞的扩增及其用途
US20210261636A1 (en) Neoantigens expressed in multiple myeloma and their uses
JP7644111B2 (ja) がんを治療するための腫瘍内及び／または静脈内投与用組み換えｍｖａウイルス
JP2025124655A (ja) 新規な癌抗原及び方法
US20240254161A1 (en) Neoantigens Expressed In Ovarian Cancer And Their Uses
WO2022009052A2 (en) Prostate neoantigens and their uses
RU2841311C1 (ru) Неоантигены, экспрессируемые при множественной миеломе, и их применение
EA047647B1 (ru) Неоантигены предстательной железы и их применение
HK40055542A (en) Prostate neoantigens and their uses
HK40085962A (en) Neoantigens expressed in ovarian cancer and their uses
EA051127B1 (ru) Неоантигены, экспрессируемые в раке яичника, и их применение
HK40071804A (zh) 与小鼠和人成纤维细胞激活蛋白(fap)交叉反应的抗犬成纤维细胞激活蛋白单克隆抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20701888

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: CR2021-000370

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: LK/P/1/21855

Country of ref document: LK

ENP Entry into the national phase

Ref document number: 2021539906

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3126462

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021013507

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 2020207641

Country of ref document: AU

Date of ref document: 20200109

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: NC2021/0010006

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: DZP2021000481

Country of ref document: DZ

ENP Entry into the national phase

Ref document number: 20217025212

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2020701888

Country of ref document: EP

Effective date: 20210810

WWP Wipo information: published in national office

Ref document number: NC2021/0010006

Country of ref document: CO

WWP Wipo information: published in national office

Ref document number: CR2021-000370

Country of ref document: CR

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: 112021013507

Country of ref document: BR

Free format text: APRESENTAR NOVO CONTEUDO DE LISTAGEM DE SEQUENCIAS NOS MOLDES DA PORTARIA 405, DE 21/12/2020, POIS O CONTEUDO DA LISTAGEM APRESENTADA POSSUI CAMPO DIVERGENTE AO PEDIDO (CAMPO 141).

REG Reference to national code

Ref country code: BR

Ref legal event code: B01Y

Ref document number: 112021013507

Country of ref document: BR

Kind code of ref document: A2

Free format text: ANULADA A PUBLICACAO CODIGO 1.5 NA RPI NO 2646 DE 21/09/2021 POR TER SIDO INDEVIDA.

ENP Entry into the national phase

Ref document number: 112021013507

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210708

WWG Wipo information: grant in national office

Ref document number: 521422495

Country of ref document: SA

WWG Wipo information: grant in national office

Ref document number: NC2021/0010006

Country of ref document: CO

WWR Wipo information: refused in national office

Ref document number: CR2021-000370

Country of ref document: CR